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Introduction 
Normal flora as well as pathogenic bacteria, can induce acute and chronic 
inflammations in humans. Probably as a result of the therapeutic efficacy of 
antibiotics in the past decades there has been relatively little interest in the 
mechanisms underlying bacterially induced inflammation. However, because of 
the increase in the incidence of antibiotic resistant bacteria, the subject is 
gaining interest. It is important to investigate the inflammatory mechanisms in 
order to provide new tools for clinicians as they will have to treat the inflam-
matory symptoms as well as the infection. 
One of the major components present in Gram-positive bacteria is 
peptidoglycan (PG). It has been shown that PG possesses inflammatory 
properties similar to LPS. This suggests that PG is involved in the pathogenesis 
of inflammation induced by Gram-positive bacteria and possibly also Gram-
negative bacteria. A description of the recent work done to test this hypothesis 
is given in the first part of this introduction. In the second part of this chapter 
special attention is given to the detection of PG in tissues. The presence of PG 
in tissues is a prerequisite for the induction of inflammation by PG products. 
The presence of PG in tissues implicates the presence of PG degrading systems, 
necessary to prevent the inflammation. In the last Palt of this chapter, an 
overview is given on the PG degrading systems available in humans. 
1.1 INFLAMMATORY PROPERTIES OF PEPTIDOGLYCAN 
PG is present in the cell walls of most bacteria and is the major consti-
tuent of Gram-positive cell walls (Fig. I, upper palt). It is composed of alterna-
ting N-acetyl glucosamine (GlucNAc) and N-acetyl muramic acid (MurNAc) 
forming long sugar chains which are interlinked by peptide side ch~ins resul-
ting in a large, complex macromolecule (Fig. 2). This bag-shaped molecule 
surrounds the cell and gives it the strength to withstand the turgor pressure 
exelted by the cytoplasm. 
During a bacterial infection PG and several other cell wall components 
are implicated in the pathogenesis of the inflammation. In Gram-negative 
infections, endotoxin (a lipopolysaccharide-protein complex from the outer 
membrane; Fig. I, lower part) is a well known activator of the innate immune 
system. DlII'ing Gram-positive infections, when no endotoxin is produced, PG is 
able to induce similar effects as endotoxin. The activation of complement [1-3], 
macrophages and monocytes [4], but also the activation of granulocytes [5,6] 
and upregulation of adhesion molecules on endothelial cells [7] are shared 
propelties of endotoxin and PG. Pro-inflammatory cytokines such as IL-I, IL-6, 
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IL-8 and TNF-a can mUTIlc the whole spectrum of toxicity caused by endo-
toxin and PG. This may explain why septic shock caused by Gram-positive 
bacteria and Gram-negative bacteria have common cytokine induced characte-
ristics [8]. Gupta et al. [9] recently described that the tyrosine phosphorylation 
of several proteins and the activation of kinases in macrophages were identical 
upon stimulation with PG or endotoxin, which supports the hypothesis that PG 
and endotoxin activate macrophages through similar mechanisms. 
IL-I and TNF-a appear to play predominant roles in the normal physio-
logic inflammatolY response. Many of the physiological functions of IL-I 
overlap the functions of TNF-a, both stimulating the non-specific host respon-
se. However, when excessive concentrations occur, the beneficial responses 
exelted by these cytokines are often outweighed by adverse physiologic effects. 
In sepsis, these two cytokines mediate the septic state by influencing vascular 
resistance and permeability, cardiac function and bone marrow function. They 
also stimulate the production of other inflammatory cytokines. Pmticularly 
important is the local release of IL-8, which recruits and activates neutrophils, 
resulting in tissue damage and organ dysfunction [10]. In addition to IL-8, 
TNF-a and IL-I induce the secretion of other mediators, including IL-6, 
platelet-activating factor, prostaglandins and leukotrienes [11,12]. The induction 
of inflammatory cytokilles is therefore an impoltant mechanism in the pathoge-
nesis of PG-illduced inflammation. 
To study the inflammatOlY properties of PG, experimental models for 
peltussis, meningitis, sepsis and arthritis have been applied. A summary of 
these models as provided in this introduction gives an idea on the wide range 
of inflammatory propelties exelted by PG in vitro and in vivo. 
Figurc 1. Gram-positivc and Gram-negativc ccll wall composition. 
Upper part Diagrammatic representation of a generalised Gram-positive cell wall-plasma 
membrane complex. The plasma membrane is shown as being composed of protein (P). phospholi-
pid (PL), glycolipid (GL), Iipoteichoic acid (LTA) and wall tcichoic acid (WTA), which is 
connected to the multiple layered peptidoglycan sugar chains. The composition may vary between 
different Gram-positive bacteria. 
Lower part Diagrammatic representation of a generalised Gram-negative bacterial cell envelope. 
The inner leanet of the bilayer of the outer membrane is shown to be composed of phospholipid 
(PL), protein (P) and lipoprotein (LP) which is covalently linked to the thin peptidoglycan layer in 
the periplasmic space between the plasma membrane and the outer membrane. Smooth and rough 
variants of lipopolysaccharide (sLPS and rLPS) are present in the outer membrane. The three 
regions of LPS are depicted as black lines (lipid A, fatty acids couplerl to disaccharide diphosphate 
units), black rectangle (core polysaccharide) and open squares (units of Q-polysaccharides repealed 
up to 25 times). LP is present in the outer membrane. The composition may vary between different 
Gram-negative bacteria. 
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1.1.1 In vitro models for inflammation 
Most of the in vitro models to study the pathogenesis of inflammation 
caused by bacterial products use peripheral blood monocytes, whole blood or 
macrophage cell lines. Gold et al. [13] and Chedid et al. [14] showed for the 
first time that PG products were able to induce release of IL-I from purified 
monocytes in vitro. Purified high molecular weight PG from Staphylococcus 
epide/'midis stimulated IL-I, IL-6 and TNF-a release by human peripheral 
blood monocytes [15]. High molecular weight PG was required for the inducti-
on of chemiluminescence, an activation marker, in human polymorphonuclear 
leukocytes. Chemiluminescence induced by low molecular weight PG obtained 
after sonication of the isolated cell walls, was much lower «20%) than with 
high molecular weight PG [6]. Heumann et al. [16] stimulated human monocy-
tes with purified cell wall preparations containing mainly PG from 10 different 
Gram-positive bacteria, which were all able to induce TNF-a release. 
Vowels et al. [17] investigated the production of IL-8, IL-I J3 and TNF-a 
by human monocyte cell lines and treshly isolated peripheral blood monocytes 
after stimulation with PG- containing culture supernatants of Propionibacterium 
acnes, implicated in the pathophysiology of acne vulgaris. Fractionation of the 
supernatants by selective dialysis showed that most of the original cytokine 
inducing activity was present in the fractions with a molecular weight between 
3 and 30 kDa. After treatment of the culture supernatants with lysozyme, the 
IL-8 and TNF-a production were approximately 50% lower than was found 
with untreated culture supernatants. This shows that the molecular weight of 
PG is impOltant for the induction of cytokines in these in vitro assays. The 
studies of Dobrina et al. [7] showed that the CDII/CDI8 adhesion complex 
was upregulated after a 4 hour incubation of human endothelial cells with 
purified PG from the Gram-negative Leptospira iclerohaemorrhagiae, resulting 
in an increased cell adhesiveness for neutrophilic granulocytes. 
Small muramyl peptides, the monomers of macromolecular PG, aw also 
able to induce cytokine release by monocytes. It was demonstrated that the 
anhydro disaccharide tetrapeptide (Fig. 3) strongly induced IL-I and IL-6 
mRNA production in human monocytes [18]. The same product was investiga-
l"igure 2. Upper part Alternating N-ncet)'! glucosamine (G) and N-ncet)'! muramic acid (M) are connected by peptide 
bonds resulting in a cross-linked network. Gram·positive peptidoglycan (len) is morc extensively cross-linked than Gram-
negative (right) peptidoglycan. 
Lower part Detailed structures of muramyl peplides. The interpeptide bridges. I, are variable between strains. N-
acetylmuramyl-L-alanine amidase (NAMLAA) hydrolyses the lactate bond between N·acel),l muramic acid (1'.lurNAc) 
and the first aminoacid of the peptidoglycan chain L·alanine ( ..... ). Lysozyme hydrolyses the bond between MurNAc and 
GlucNAc ( ••• ». Some bacteria can contain an extra a·acetyl group on the C-6 atom of MurNAc (box). 
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ted in a different test system. Bordetella pertllssis, the causative organism of 
whooping cough, was used in an in vitro model with cultured hamster trachea 
epithelial cells [19). A PG-containing fraction inhibited DNA synthesis in these 
cells. The component responsible for this effect was found to be the anhydro-
disaccharide tetrapeptide subunit of PG, also called tracheal cytotoxin (TCT) 
[20). Wilson et al. [21) found that loss of ciliated cells in human epithelial 
biopsies could be induced by TCT. In later studies Nixon Heis et al. [22) 
showed that intracellular IL-I is produced by tracheal epithelial cells after TCT 
treatment and hypothesized that TCT toxicity might be mediated through IL-I 
and nitric oxide production. In a structure-activity study the peptide side chain, 
which is normally linked to MUl'NAc in PG (Fig. 2), was shown to be the 
minimal structUl'e of TCT which was fully toxic in the assay using tracheal 
epithelial cells (Fig. 3) [23). 
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f'igure 3, Tracheal cytotoxin (Tel). The larger box contains the I?,ctyltctrapeptide portion of TCT, which is sufficient to 
reproduce the TCT toxicity of the complete molecule. The smaller box contains the smallest fragment shown to elicit 
measurable toxicity in respiratory epithelial cells (23]. 
In conclusion, the combined results of the in vitro studies show that PG, 
derived fi'om normal flora bacteria or pathogens, is capable of inducing most of 
the effects seen in local or systemical inflammation. 
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1.1.2 In vivo mo(leIs for inflammation 
The in vivo studies on chronic inflammation are mostly performed using 
peptidoglycan polysaccharide complexes (PG-PS). Systemic inflammations 
caused by these less well-defined complexes show that PG-PS can induce 
multisystem disease [24]. An animal model for chronic, erosive arthritis in rats 
can be used to study the involvement of PG in the pathogenesis of the disease. 
In susceptible rats, e.g. Lewis rats, a single intraperitoneal (i.p.) injection of 
cell wall fragments (CWF) causes an acute polyalthritis, followed by a chronic 
persistent althritis [25]. In vitro degradation of CWF by mutanolysin (a PG 
degrading enzyme from Streptomyces glohisporlls) resulted in loss of the 
31thropathic propelties of the cell walls, indicating the potent role of PG in the 
pathogenesis of this disease in Lewis rats [26,27]. 
Studies of classic adjuvant induced arthritis, where rats are immunized 
subcutaneously with PG products ground in mineral oil, have demonstrated a 
role for the chemically defined muramyl dipeptide (MDP) subunits of PG [28]. 
The arthropathic activity of MDP depends on the mineral oil used and the 
amino acids coupled to the muramic acid [29]. However, when injected i.p. in 
aqueous suspension, neither PG nor its subunit MDP induced chronic 31thritis 
[30]. Although in the i.p. route of arthritis induction in rats the use of high 
molecular weight PG is essential, lysozyme-solubilized CWF are still capable 
of inducing arthritis in the adjuvant model [31 and chapter 5], indicating that 
high molecular weight PG is not a prerequisite for althritis induction in this 
model. Therefore, the adjuvant arthritis model was used in chapter 5 as a tool 
to investigate the inflammatory propelties of CWF after enzymatic degradation. 
A structure-activity study was performed by Tuomanen et al [32] and 
Burroughs et al. [33]. They used a rabbit model to study the pathogenesis of 
bacterial meningitis by injecting intracisternally 17 different muramyl peptides 
derived f1-OIll PG of the Gram-negative Haemophillls injlllellzae, together repre-
senting 96% of the total PG. The ability to induce leukocytosis, blood-brain 
barrier permeability and brain edema varied between different muramyl 
peptides, suggesting that each muramyl peptide interacts with host defenses in a 
specific and individual manner. 
Another property of muramyl peptides is the sleep-promoting effect 
[reviewed in 34]. The PG subunit MDP was shown to enhance slow-wave sleep 
in rabbits [35] and other mammals. IL-l can mimic these somnogenic effects 
and it was hypothesized that the propelties of MDP are mediated through IL-l, 
which cytokine, as described above, is released by monocytes upon activation 
by PG during a bacterial infection. 
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1.1.3 Other pro-inflammatory components of bacterial cell walls 
In Gram-positive bacteria, PG accounts for more than half of the cell 
wall mass [36], while in Gram-negative bacteria the cell wall is no more than 3 
PG layers thick [37]. In Gram-positive bacteria (Iipo)teichoic acids (LTA) and 
poly-saccharides account for most of the other half of the cell wall mass. In 
Gram-negative bacteria smooth and rough variants of (Jipo )polysaccharides 
(LPS) and (Iipo)proteins form the bulk of the cell wall besides the PG (Fig. 1). 
A summaty of all the known cell wall components in Gram-negative and 
Gram-positive bacteria which possess inflammatOlY capacities is given in Table 
1. LPS and LTA have been shown to possess similar inflammatOlY propelties 
as PG. Endotoxin, a complex of LPS and (Iipo )proteins, has been shown to 
possess a higher inflammatory potency than LPS, LTA or PG [39,40]. Since 
PG is a major inflammatory component of Gram-positive bacteria, this thesis 
emphasizes the role of PG in the pathogenesis of inflammation. 
Table 1. Inflammatory cell wall components from Gram-positive and Gram-negative 
bactcl'ia 
Gram-positive 
Teichoic acids 
Lipoteichoic acids 
Lipoarbinomannans 
Purified proteins 
Mycobacterial heat 
shock protein 
Protein A 
From reference 35. 
Gram-negative 
Lipopolysaccharide 
Lipid A 
Lipid A-associated proteins 
Outer membrane proteins 
Porins 
Gram-positive and negative 
Cell surf.'lce proteins 
Surface-associated proteins 
Fimbriae and pili 
Lipopeptides 
Lipoproteins 
Muramyl peptides 
Peptidoglycan 
Polysaccharides 
Toxins 
1.2 DETECTION OF PEPTIDOGLYCAN IN INFLAMED AND 
NORMAL TISSUES 
It is hypothesized that PG is involved in the pathogenesis of inflamma-
tion, as for instance in atthritis. The presence of PG in relevant tissues, 
however, is a prerequisit for this hypothesis. Most studies investigating the 
presence of PG in tissues focus on the detection of muramic acid (Mur), the 
16 
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characteristic aminosugar (after release of the N-acetyl group of MurNAc by 
acid hydrolysis) in the glycan backbone of PG. However, also radioactively 
labeled PG-PS has been used in an atthritis model (41). After i.p. injection into 
rats, [125I)_PG_PS localized in liver and spleen as high molecular weight PG 
and in synovia as partially degraded lower molecular weight PG (41). 
Gilbert and Fox (42) measured the levels of rhamnose polysaccharide 
and Mur in tissues using a combination of gas chromatography and mass 
spectrometry. They used streptococcal PG-PS in the i.p. model of arthritis 
induction and found a time-dependent decrease of Mur levels in liver and limbs 
of rats. Mur was still detectable 63 days after injection in both liver and limbs. 
In the same arthritis model a fluorescein-labeled streptococcus-specific antibody 
was used to detect the presence of streptococcal antigens in tissues by immuno-
histochemical techniques. The streptococcal cell wall material accumulated 
rapidly in the liver, spleen, lymph nodes and synovia where it remained 
detectable for more than 90 days (43). 
In humans the first results were obtained by Martin et al. (44), who 
showed the presence of PG monomers in human urine after penicillin administ-
ration. This indicates that small PG fragments, released upon antibiotic treat-
ment (45), can be cleared from the circulation by the kidneys. Mur was also 
detected in the synovial fluids of patients with acute inflammatory arthritis of 
unclear origin but who had a history of bacterial disease (46), providing 
support for the idea that these PG products present in the synovia are able to 
playa role in the pathogenesis of the inflammation. 
Although Fox and Fox (47) were not able to demonstrate Mur in 
normal serum, there is accumulating evidence that also without introduction of 
PG by injection or infection, tissues of rats and humans contain PG. In periphe-
ral blood leukocytes from 21 of 98 healthy human subjects, Mur could be 
detected using a combination of gas chromatography and mass spectromelty 
(48). Leukocytes from umbilical vein blood from 41 newborns were Mur 
negative. Since newborns lack gut flora, intestinal absorption of bacteria or of 
their degradation products was believed to be the most likely explanation for 
the presence of Mur in the peripheral blood leukocytes. Immunohistochemical 
studies using a monoclonal antibody against PG-PS revealed the presence of 
PG-PS containing cells in spleen of conventional rats (49). Using immunohis-
tochemistry the presence of PG-PS was also detectable in the bowel-wall in 
humans and a connection with Crohns disease has been proposed [50). Sen and 
Karnovsky [51) found Mur in· brain, liver, and kidneys of conventional rats. 
The last three studies indicate that PG is present in tissues even without an 
inflammation, which suggests that the PG found in tissues can originate from 
17 
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normal flora bacteria and might therefore be capable of maintaining a chronic 
inflammation. 
Together with the work presented in chapters 2 and 3 of this thesis, 
these results show that PG is detectable in human tissues, which sup pOlis the 
hypothesis that PG can playa role in the pathogenesis of inflammations with 
unknown etiology. 
1.3 PEPTIDOGLYCAN PERSISTENCE VERSUS DEGRADATION; 
THE HUMAN ENZYMES 
1.3.1 Persistence of peptidoglycan 
When invading bacteria or their PG-containing CWF enter our system, 
the CWF are rapidly cleared through the action of hydrolytic enzymes present 
in serum and phagocytic cells. Neveliheless, PG does occur in human tissues 
and it has been shown in animal models that injected PG can persist for a long 
time. The inflammatory properties of PG and its persistence in tissues justifies 
to study the properties of PG in relation with its resistance to hydrolytic 
degradation. 
To investigate the ability of PG to persist in tissues, PG from different 
sources was injected i.p. into rats. The injected PG could be detected in 
macrophages for more than 90 days. Lichtman et al. [52] showed that PG laden 
macrophages were able to induce inflammation in vivo. They transplanted 
livers of rats, injected i.p. with PG, into a second rat with preinjured joints, 
resulting in a reactivation of arthritis. This finding suggests that PG present in 
macrophages can playa role in the pathogenesis of inflammation. 
Rat macrophages and human monocytes were shown to process 
streptococcal cell walls in vitro [53]. Similar results were obtained using 
Bacillus slIbtilis PG and a mouse macrophage cell line [54]. Macrophages were 
also shown to digest radioactively labeled cell walls from staphylococci. These 
cell wall laden macrophages then excreted low-molecular weight PG fragments, 
which were shown to possess somnogenic and pyrogenic activities in rabbits 
[55]. 
The relation between persistence in tissues and resistance to degradation 
by lysozyme was clearly shown when PG-PS from group A and group 0 
streptococci were compared [41]. Group A PG-PS were more resistant to in 
vitro lysozyme degradation and were also shown to persist longer in vivo than 
group 0 PG-PS. 
The experiments using animal models all indicate that macrophages 
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play an impOltant role in clearing and degrading circulating high molecular 
weight PO, but also that CWF can persist in macrophages, retaining their 
inflammatory properties. 
1.3.2 Peptidoglycan degrading enzymes in humans 
In humans, three different hydrolytic enzymes are known to degrade 
peptidoglycan; lysozyme, N-acetylglucosaminidase and N-acetylmuramyl-L-
alanine amidase. The relationship between the structure of PO and its resistance 
to degradation by lysozyme has been the subject of several investigations. The 
resistance of PO to degradation by lysozyme was shown to depend upon the 
degree of a-acetylation [56]. This can be explained by the finding that the 
presence of a-acetyl groups on the glycan backbone (Fig. 2) of PO results in a 
weaker affinity of lysozyme for PO. 
The relation between the in vivo inflammatory capacity and the 
susceptibility to lysozyme degradation was shown using the i.p. route of 
arthritis induction in rats. The most resistant PO preparations were the most 
potent inducers of atthritis [57,58]. Most interestingly, the amount of a-acetyl 
groups present in PO can be influenced by treatment with antibiotics. Staphylo-
coccus aureus treated with Clindamycin resulted in PO with an increased 
number of a-acetyl groups and this PO was less sensitive to lysozyme degrada-
tion [59]. This might be an important side effect of treatment with Clindamycin 
and similar antibiotics. 
N-acetylglucosaminidase is a common enzyme present in human sera 
and other tissues [60]. Its primary function is the degradation of oligosaccha-
rides containing ll-glucosam ide linkages, present on many glycoproteins. 
Olucosaminidase activity was also shown to be present in a granule extract 
from human neutrophils, which was shown to be capable of hydrolysing free 
N-acetylglucosamine (OlucNAc) groups from non-reducing ends of the PO-
backbone [61]. The effect of N-acetylglucosaminidase degradation of PO on the 
inflammatory properties of PO has not been investigated. It is, however, 
reasonable to assume that this enzyme has very little effect on these properties 
because it can only hydrolyse one OlucNAc molecule from the long sugar 
chain of macromolecular PO. The properties of muramyl peptides are also not 
likely to be affected by N-acetylglucosaminidase since it has been shown that 
OlucNAc is not essential for the inflammatory properties of muramyl peptides 
[34]. 
N-acetylmuramyl-L-alanine amidase (NAMLAA) was first described 
by Pelzer in 1963, who showed that its enzymatic activity was present in 
Escherichia coli [62]. It was shown that NAMLAA specifically hydrolyses the 
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lactamide bond which links MurNAc of the polysaccharide chains to L-alanine 
of the peptide side chain (Fig. 2). Since then NAMLAA enzymes have been 
pl\l'ified fi'om Staphylococcus areus [63], Bacillus subtilis [64] and bacteriopha-
ge T7 [65]. The involvement of the enzyme in autolysis of pneumococci was 
shown [66] and the lysis was shown to be dependent on the presence of 
teichoic acids [67]. Autolytic microbial enzymes like NAMLAA were not 
involved in the lysis after the pneumococci were ingested by phagocytes [68]. 
The first bacterial gene encoding NAMLAA has been identified in Staphylo-
coccus aureus [69] and recently this enzyme has been shown to possess cluster 
dispersing activity [70]. Mutants without the gene were shown to grow in giant 
clusters, suggesting that NAMLAA in these cells is involved in cell separation 
after cell division. Cytoplasmic NAMLAA was also shown to be involved in 
beta-Iactamase regulation and cell wall recycling [71]. 
In human sera NAMLAA activity was reported for the first time by 
Laddie et al. [72] and the enzymatic activity of the enzyme was determined by 
Valinger et al. [73]. They showed that NAMLAA has the same enzymatic 
hydrolytic activity as the bacterial enzyme. The result of such hydrolysis is 
degradation of macromolecular PG to small PG products, which can be 
excreted in the urine [44,45]. A good colorimetric method for the detection of 
NAMLAA activity in serum has been described by Hazenberg and De Visser 
[74]. The detection limit of this assay corresponds to the activity in 200 times 
diluted human serum and this assay proved to be highly valuable for the 
characterization of NAMLAA from human serum, as is described in chapter 4. 
Further studies on the purification and characterization of the enzyme have 
been performed by Tomasic et al. [75], Mollner and Braun [76], de Pauw et al. 
Table 2. Localization of PC degrading enzymes in human body fluids 
Human body fluids lysozyme N~acetylglucosaminidase 
saliva + ? 
cerebrospinal fluid 
(without pathological signs) ± ? 
milk ++ ? 
synovial fluid ? ? 
serum + + 
urine ? 
tears ++ ? 
-: undetectable, ±: lower than in serum, +: equal to serum, ++: higher than in serum. 
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[77] and Vanderwinkel et al. [78,79], but the purification to homogeneity of 
NAMLAA remained problematic. Therefore the biological role of this human 
enzyme could not be investigated before. 
1.3.3 Localization of peptidoglycan-degrading enzymes 
The localization of lysozyme [80], N-acetylglucosaminidase [60] and 
NAMLAA might be important for the biological role of these enzymes. Table 2 
gives a summaty of the localization in human body fluids. The precise localiza-
tion of NAMLAA and the comparison with lysozyme distribution in human 
mononuclear cells is described in chapter 6 of this thesis. 
1.4 SCOPE OF THE THESIS 
PG polymers and monomers have potent biological effects. A major 
factor herein is the ability of PG to persist in tissues. The presence of PG in 
tissues is a prerequisite for the induction of perpetuating effects in vivo. To 
investigate whether PG is present in human tissues, we used a monoclonal 
antibody, recognizing PG, for immunohistochemical studies. The immunohisto-
chemical detection of PG products in synovial tissues of rheumatoid arthritis 
patients and healthy controls is described in chapter 2. The extraction of a high 
molecular weight carbohydrate enriched fraction from human spleens and the 
biochemical determination of Mur, the characteristic aminosugar of PG in this 
extract, is described in chapter 3. 
The persistence of PG in tissues depends on its degradability by 
hydrolytic enzymes. In this respect, lysozyme has been investigated extensively 
by other investigators. The relatively new mammalian NAMLAA, which 
cleaves the peptide side chain of the PG sugar backbone, has so far not been 
velY well characterized. We hypothesize that NAMLAA has a potent role in the 
inactivation of PG products. In order to investigate this hypothesis, NAMLAA 
was purified and biochemically characterized (chapter 4). The biological 
activity of NAMLAA in relation to the inflammatory properties of NAMLAA 
digested PG was then investigated using the purified NAMLAA (chapter 5). 
The localization of NAMLAA might be impOltant for the biological 
function of this enzyme. In order to study the localization of NAMLAA, a 
monoclonal antibody has been prepared against NAMLAA and this antibody 
has been used for immunohistochemical studies and electron microscopy 
(chapter 6). The results in chapter 7 compare the presence of NAMLAA and 
lysozyme in cerebrospinal fluid and sera of bacterial meningitis patients and 
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presence of PG in synovial tissues 
ABSTRACT 
In previous studies, using an animal model, human bacterial flora derived 
peptidoglycan polysaccharides were shown to be arthropathic after a single 
subcutaneous injection. A prerequisite for proof of the hypothesis that bacterial 
products from the normal resident flora are involved in the immune reaction of 
human chronic polymthritis of unknown etiology, is the presence of (hese 
antigen's in synovial tissue. 2E9, a monoclonal antibody we developed against 
intestinal peptidoglycan polysaccharides was used in a histochemical study in 
rats and stained macrophages in the spleen red pulp. In this study human 
synovial tissues from 10 RA and 20 non-RA patients were stained with 2E9. 
We found that 8 out of 10 RA had 2E9 positive macrophages and dendritic 
cells in their synovia. A significant difference was observed with the control 
group in which 7 out of 20 were positive. No positive cells 01' staining of the 
matrix were found in the cartilage of 6 RA patients. These results show that 
exogenous bacterial antigens are present in synovial tissue macrophages and 
dendritic cells. It was concluded that the unknown antigen in the immune 
reaction in RA is not necessarily endogenous. 
INTRODUCTION 
There is evidence that supports a central position for the T cell in rheumatoid 
mthritis (RA) [I]. Specific CD4+ T cells react with antigenic peptides presented 
by Major Histocompatibility Complex (MHC) class II molecules on antigen 
presenting cells. The result is that activated T cells stimulate other cells, leading 
to the production of effector molecules such as cytokines and degradative 
enzymes. Synovial MHC class II dependent T cell activation is considered the 
primary driving force in development of RA, the antigen in the trimolecular, 
MHC-(super)antigen-T cell receptor complex, however, is not identified. 
Although, tentative candidates are generally believed to be endogenous, 
exogenous antigens could not be excluded. 
We hypothesize that bacteria or bacterial products from the normal 
resident flora are implicated in the immune reaction of chronic human polyar-
thritis of unknown etiology like RA. In previous studies, using a rat model, the 
arthropathic properties of the most abundant groups of bacteria in the human 
flora were investigated. Cell wall fragments (CWF) from obligate anaerobic 
Eubacterium and Bifldobacterium species, wi th peptidoglycan as a major 
component, induced a severe chronic polyarthritis after a single intraperitoneal 
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or subcutaneous (in oil) injection [2,3,4]. Although the faecal flora of RA 
patients and healthy subjects was different, EubacteriulII and BijidobacteriulII 
were present in both flora in a very high number (109-10 10 per gram stool). 
CWF of Eubacterium aerofaciens strains isolated from the flora of patients and 
controls were arthropathic [5]. Soluble peptidoglycan polysaccharide complexes 
originating from the obligate anaerobic flora were purified from human 
intestinal contents by gel filtration. The complexes isolated from ileostomy 
fluid, that proved to be less degraded by intestinal enzymes, induced chronic 
a11hritis in rats after injection in the base of the tail [6]. From that study we 
concluded that the human intestinal flora contains soluble bacterial cell wall 
derived products with althropathic properties. 
If RA is a T cell dependent immune response to peptidoglycan-poly-
saccharides of the bacterial flora, these antigens must be present in synovial 
tissues. An immunohistochemical study with monoclonal antibody (2E9) 
directed against intestinal peptidoglycan polysaccharides, which was developed 
in our laboratory, showed that the red pulp of rat spleen is scattered with 
positively staining macrophages [7]. FUl1her studies with human tissues showed 
that peptidoglycan-polysaccharides positive cells (2E9, positive) were present in 
bowel wall and spleen [8,9]. Peptidoglycan was also isolated from the human 
spleen and biochemical characterized [9]. The latter showed that the presence 
of peptidoglycan is human tissues is probably normal feature. In the present 
study we investigated the presence of bacterial antigens in human synovial 
tissues using this unique monoclonal antibody. The detection of bacterial 
product in synovial tissues in RA is, to our knowledge, a novel finding. 
MATERIALS AND METHODS 
Patients 
Synovial tissues were obtained at the time of reconstructive surgery from the knees or 
hips of 10 patients of definite or classical RA according to the ARA criteria [10]. Non-rheuma-
toid synovial tissue was obtained from knee biopsies of 25 patients with a non· inflammatory knee 
injul)'. The average ages of the RA patients (3 males and 7 females) and of the control group (20 
males) were 68 and 28, respectively. 
Cartilage was obtained from another group of 6 RA patients. The average age of these 
RA patients (all female) was 61. Synovial tissues and cartilage were stored at -70°C until use. 
Preparation of cryostat sections 
Frozen serial sections (6 ~m) were cut on a Reichert-lung 2800 Frigocut cryostat. The 
synovial tissue sections were placed on poly.L-lysine-coated (Sigma, st. Louis, MO) microscopic 
slides and the cartilage sections were placed on 3-amino-propyltriethoxysilane-coated slides (Sig-
ma, St. Louis, MO). After drying in the air for J hour the sections were stored at _20°C. 
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Immunohistochemistry 
To study the general morphology the thawed sections were dipped in phosphate-buffered 
saline (PBS) with 4% formaldehyde and stained with hematoxylin and eosin. For immunohisto-
chemist!)' the slides were fixed for J 0 minutes in acetone. After rinsing in PBS with 0.2% bovine 
serum albumin (BSA). the sections werc incubated for I hour at room temperature with 70 J.l1 
diluted monoclonal antibody. The monoclonal antibodies were used as listed in Table l. 2E9 is a 
monoclonal antibody with the JgG3 isotype and NS7, with the same isotype, is used as a negative 
control monoclonal antibody. 2E9 is directed against intestinal flora derived peptidoglycan poly-
saccharides from human and rat facces [7]. Inhibition assays with ELISA showed that peptidogly-
can from Escherichia coli, Micrococcus Iysodeikliclis and Brevibacterium divaricatum inhibited 
the reaction of 2E9 with the intestinal flora derived peptidoglycan [7, M.P. Hazenberg, personal 
communication]. The sections were subsequently rinsed in PBSIBSA and incubated for 30 min at 
room temperature with rabbit anti-mouse immunoglobulin (Z259, Dakopatts. Denmark) diluted 
1:20 in PBSIBSA with 1% nonnal human serum. After rinsing in PBSIBSA. a 1:40 dilution of 
alkaline phosphatase-mouse-anti-alkaline phosphatase complcx (APAAP) (D65 I, Dakopatts, 
Denmark) was applied for 30 minutes. The substrate used to develop the stain consisted of 
0_012% (w/v) naphthol-ASMX phosphate, 0.025% (w/v) fast blue BB base, and 0.025% (w/v) 
levamisole (all from Sigma, st. Louis, MO). After 45 minutes incubation at room temperature in 
the dark, the sections were rinsed in PBSIBSA followed by distilled water and mounted in 
Kaiser's glycerol gelatin (Merck, Darmstadt, Germany). 
Table 1 Monoclonal antibodies used in the study 
code specificity concentration reference 
used 
2E9 peptido glycan-po I ysaccharides 10 I'g/ml [7] 
2-4 muramyl-dipeptide 10 I'g/ml [II 1 
NS7 sheep red blood cells 10 I'g/ml TIB II 4, A TCC 
RV202 vimentin I:JO [I2l 
Mac macro phages 1:100 M178, Dako 
L25 dendritic cells 1:500 [13] 
RFDI dendritic cells 1:500 [14] 
Leu4 CD3 (T cells) 1:50 347340 BD 
Immuno double-staining 
For double staining with acid phosphatase, the staining with the monoclonal antibody 2E9 
was carried out as described above. After the incubation with the alkaline phosphatase substrate, 
acid phosphatase activil)' was demonstrated as described by Lojda et al [15]. 
To study how many 2E9-positive cells in the synovial tissue were mast cells, a double 
staining with toluidine blue was used. The staining with the monoclonal antibody 2E9 was 
carried out as described above. After the incubation with the alkaline phosphatase substrate the 
section were incubated for I minute with the 0.5% (w/v) toluidine blue (BHD, GUIT) and scored 
immediately. 
For double staining with two monoclonal antibodies the synovial tissue cryostat sections 
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were acetone fixed. Endogenous peroxidase activity was blocked by 0.1 % (w/v) phenylhydrazini· 
urn chloride (Sigma, St. Louis, MO) in PBS, for 1 hour at 37°C. After rinsing in PBSIBSA the 
sections were incubated with the pcptidoglycan~polysaccharide-specific monoclonal antibody 2E9 
for I hour at room temperature. As a second step a peroxidase conjugated rabbit anti-mouse 
immuuoglobulin (PI61, Dakopatts, Denmark) was used in a 1:250 dilution in PBSIBSA with 1% 
normal human senlln. After 30 minutes incubation and rinsing with PBS/BSA, the sections were 
incubated with the second monoclonal antibody (RFDI, L25 or Leu4, Table I) for I hour at 
room temperature. The staining was detected by the immuno alkaline phosphatase anti-alkaline 
phosphatase (APAAP) method as described above. After the incubation with the alkaline 
phosphatase substrate the sections were rinsed in PBSIBSA followed by 0.2 M sodium acetate 
buffer pH 4.6, and incubated with the peroxidase substrate 3-amino-9·ethylcarbazole for 30 
minutes. Finally the sections were rinsed in PBS/BSA and distilled water and mounted in 
Kaiser's glycerol gelatin (Merck, Damlstadt, Gennany). 
Comparison of the results 
The total area of the synovial sections was measured using a calibrated measuring ocular 
(Kpl. 8x, Zeiss, Germany). Per section the total numbers of 2E9 positive cells was dctennined. 
To be able to compare the different patients, the number of positive cells per mm2 was calculat-
ed. The Mann-Whitney U test was used to calculate the statistical differences. 
RESULTS 
Rheumatoid synovial tissue 
Hematoxylin and eosin staining of the synovial tissues showed nodular 
infiltrates in 8 out of the 10 RA patients, Immunohistochemical staining with 
2E9 specific for intestinal peptidoglycan polysaccharides showed that in the 
same 8 patients 8.3 (± 3.2) cells were positive per 10m2 synovial tissue. Two 
patient tissues were completely negative for 2E9, The staining was granular and 
restricted to the cytoplasm, The positive cells were found in the synovial lining 
as well as in the subsynovial layers (Fig. I), Sometimes 2E9 positive cells were 
localized adjacent to small vessels. Cytochemical staining with acid phosphatase 
showed double positive cells in both areas (Fig. 2). 
Figure 1. Immunohistologic staining of the subsynoviallayer of a RA palient. 
The 2E9 positive cells are stained (original magnification SOx). 
Figure 2. Immunohistologic double staining of the synovium of a RA patient. 
The 2E9 and acid phosphatase double positive cells are stained. Especially in the synovial lining there are cells present 
positive for both stainings (original magnification 50x). 
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In synovial tissue of two patients with the highest number of 2E9 positive cells, 
double staining with RFD I and L25, both markers for dendritic cells, was 
performed and double staining cells were identified. Staining with 2E9 and 
toluidine blue showed that a minority of the 2E9 positive cells were mast cells. 
No clustering of the 2E9 positive cells in infiltrated areas was observed. 
However, in a staining of serial sections of a T cell infiltrate with numerous 
CD3 positive cells, we found also some 2E9 positive cells in the same area. 
Staining with 2-4 was negative in synovia of all RA patients. 
Non-rheumatoid synovial tissue 
Hematoxylin and eosin staining of the synovial tissues showed no 
infiltrations in the 20 control subjects. In 2 subjects 2E9 positive cells were 
found at the same frequency as in positive RA patients (6.2 and 8.7 cells per 
mm2), in 5 subjects 0.3 to 2.8 positive cells per mm2 were observed and in 13 
subjects no positive cells were found. Staining with 2-4 was negative in all 
synovia. 
Cartilage 
The staining of the cartilage of 6 RA patients with 2E9 and 2-4 showed 
no positive staining. In one sample some synovial tissue was also present 
besides the cartilage. In this tissue 2E9 positive cells were found. A mono-
clonal antibody specific for vimentin, stained the cartilage sample heavily, 
showing that negative results with 2E9 were not due to the staining procedures, 
that were used. 
DISCUSSION 
In a previous paper we described the monoclonal antibody 2E9 which 
recognizes a human intestinal flora derived macromolecular peptidoglycan 
polysaccharide complex and which stains macrophages in the red pulp of rat 
spleens [7], antigen presenting cells in human bowel wall [8] and spleen [9]. 
In this study 2E9 positive macrophages and dendritic cells were present in 
synovial lining and subsynovial layers of most RA patients. Their significantly 
more frequent occurrence in RA patients compared with healthy subjects 
(p~0.003) should not lead to drastic conclusions. The groups differ in age and 
sex and the influence of these parameters is unknown. The differences are due 
to the fact that most of the reconstructive surgety in RA is done at elder age 
and the non-inflammatory knee injuries are the result of sport accidents. The 
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presence of 2E9 positive cells in non RA patients indicate that the presence of 
peptidoglycan polysaccharides in this tissue is not the only important factor. 
The development of RA seems to require more than the presence of 2E9 
positive cells alone. Nevertheless in RA patients more synovia were positive for 
2E9 and also more positive cells per mm2 section were found. The serial 
sections stained with a-CD3 and 2E9, showed that in T cell infiltrations 
antigen presenting cells were present which are positive for peptidoglycan 
polysaccharides. Staining with monoclonal antibody 2-4 [12] directed to 
muramyl dipeptide was not observed in any of the synovial tissues. Obviously 
there is a difference between peptidoglycan antigens found in rat and human 
spleen were 2-4 and 2E9 staining always paralleled [8, I 0]. Perhaps this is due 
to a probably more prolonged stay of the antigen in the synovia. 
Cartilage is considered to act as a sponge (or a filter) in which large 
antigens can be trapped [16]. No positive staining was found in RA caltilage 
while synovial tissue, present in two samples, did contain 2E9 positive cells. 
We realize us that we have no proof for a direct involvement of 2E9 positive 
cells in the immune reaction in RA, but the presence of these bacterial products 
in antigen presenting cells in the vicinity of T cell infiltration in the synovia of 
RA patients is intriguing and a novel finding. 
Dendritic cells and macrophages may play an important role in the 
ongoing presentation of antigen to T cells in RA synovium as suggested by 
Thomas et al [17]. We propose that the antigen driven T cell response in RA is 
not necessarily autoreactive but could be directed to gut or other flora derived 
bacterial antigens (recognized by 2E9) in antigen presenting cells in the 
synovia. 
Studies of Lehtonen et al [18] showed that in patients with acute inflam-
matOlY arthritis of unclear origin muramic acid (specific for peptidoglycan) was 
found in synovial fluid and could therefore also be present in synovial tissue. 
The presence of biochemically detectable muramic acid or peptidoglycan in RA 
synovia remains to be determined and is under current investigation by our 
group [9]. 
At this moment we are trying to isolate the 2E9 positive cells from the 
synovial tissues and are investigating whether these cells are responsible for the 
T cell autoreactivity so often reported in the literature [19] and also found in 
our investigations [20]. 
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Detection of muramic acid in human spleen 
ABSTRACT 
In previous studies we showed that peptidoglycan polysaccharides from 
anaerobic bacteria normally present in the human gut induced severe chronic 
joint inflammation in rats. Our hypothesis is that peptidoglycan from the gut 
flora is involved in perpetuation of idiopathic inflammation. However, in the 
literature the presence of peptidoglycan or subunits like muramyl peptides in 
blood or tissues is still a matter of debate. We were able to stain red pulp 
macrophages in all six available human spleens by immunohistochemical 
techniques using a monoclonal antibody against gut flora derived antigens. 
Therefore these human spleens were extracted and after removal of most of the 
protein the carbohydrate ll'action was investigated for the presence of muramic 
acid, an aminosugar characteristic for peptidoglycan. Using three different 
methods for detection of muramic acid we found a mean of 3.3 !lmol Muramic 
acid with HPLC, 1.9 flmol with a colorimetric method for detection of lactate 
and 0.8 !lmol with an enzymatic method for detection of D-Iactate per spleen 
(D-Iactate is a specific group of the muramic acid molecule). It is concluded 
that peptidoglycan is present in human spleen, not as small muramyl peptides 
as was previously searched for by other investigators, but as larger macro-
molecules probably stored in spleen macrophages. 
INTRODUCTION 
Muramic acid (Mur) is one of the two aminosugars in the glycan 
backbone of peptidoglycan (murein). It is mostly present in an acetylated form 
i.e. N-acetylmuramic acid. Short peptides are linked to the lactyl groups of this 
molecule forming a large complex macromolecule which surrounds the cell as a 
basket around the cell membrane [29]. In this study Mur is used as a chemical 
marker for peptidoglycan polymers. Sen and Karnovsky [20] showed the 
qualitative detection of muramic acid in normal mammalian tissues. Fox and 
Fox [5] were not able to detect Mur in normal serum, which demonstrates the 
absence of appreciable amounts of circulating natural muramyl peptides. Our 
group is interested in the presence of peptidoglycan in tissues as we believe 
that such intestinal flora derived carbohydrates are impOliant for physiological 
and immunological functions in the host. Johannsen et al. [11,12] showed that 
muramyl peptides have a variety of biological actions in mammals including 
the ability to enhance sleep and body temperature. In the last 15 years many 
authors described biological activities of peptidoglycan in vivo and in vitro, all 
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indicating that peptidoglycan can influence cells like lymphocytes and macro-
phages which are involved in inflammation. Lichtman et al. [IS] showed that 
livers of rats injected intraperitoneally with peptidoglycan were able to reacti-
vate atihritis after transplantation into a second rat with preinjured joints. They 
postulate that peptidoglycan present in the liver is redistributed to other tissues 
including the injured joints where it causes reactivation of atthritis. Following 
from the studies done by Lichtman et al. it would seem obvious to look for 
large bacterial fragments in human tissues. Our group is investigating the 
relationship between arthritis and intestinal bacteria [8]. Using a rat model the 
arthropathic propelties of cell wall fragments of a number of obligate anaerobic 
bacteria belonging to the "major residents" of the intestinal flora were described 
[21,22,23,13]. Recently, we developed a monoclonal antibody against a 
bacterial flora derived peptidoglycan polysaccharide fraction from human faeces 
and found positive staining of rat spleen macrophages [14]. Therefore, we have 
strong suppOli for the presence of bacterial flora derived products in the spleen. 
In this study we analysed 6 surgically removed human spleens. Using colori-
metric Mur analysis, enzymatic determination of D-lactic acid and HPLC 
analysis, the presence of substantial amollnts of Mur was demonstrated. We 
concluded that peptidoglycan polymers are present in human spleen. 
MATERIALS AND METHODS 
Spleen 
Six sterile unfixed human splcens wcre obtained from the pathology department 
immediately aner surgery [SSDZ, Delft, The Netherlands) and kept frozen until use. In 5 patients 
[1-5] with a gastric adenocarcinoma the spleen was removed for technical reasons and in patient 
6 because of traumatic rupture. Spleen samples were aerobically and anaerobically cultured on 
bloodagarbase during 48 h at 37°C. No bacterial growth was observed. The anaerobic plates were 
cultured in a jar supplied with gaspack generator envelopes with palladium catalyst (Becton 
Dickinson). 
Immunochemical staining 
Immunohistochemic staining of the human spleen was performed according to the method 
of Kool et al. used for the staining of rat spleen [14]. The same monoclonal antibody 2E9 
(mouse IgG3) recognizing intestinal flora derived peptidoglycan polysaccharides was used. 
Staining was also perfonned with 2-4, a monoclonal antibody recognizing muramyl dipeptide 
(MOP) as described by Bahr et al. [I]. 
Spleen extraction (see figure 1) 
50-100 g minced spleen in 500-1000 ml H20 was homogenized in portions using a Virtis 
homogenizer (Virtis company, U.S.A.) at 10,000 rpm for 30 s. The homogenate was sonicated 5 
times 1 min at maximum amplitude (MSE soniprep 150, UK). Acetic acid (96%) was added to a 
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Figure 1. Flow diagram of the extraction and purification of a Mur containing fraction 
from human spleen. 
50 - toO g human spleen in 10 vol. H20 
-!-
mincing, homogenization, sonication 
-!-
acetic acid (0.2 M) extraction and 100ce heating 
-!-
10,000 x g, reduction of supernatant, 100,000 x g 
-!-
Sephadex 0-25 gel filtration of 15 ml supernatant aliquots 
-!-
Ion exchange chromatography (Dowex 50Wx4) of high molecular weight fractions 
.j, 
reduction of volume, dialysis against H20, 100,000 x g 
.j, 
.j, 
DEAE sepharose CL·6B 
-!-
dialysis, reduction of volume 
referred to as B 
-!-
10 ml supernatant referred to as A 
-HPLC analysis of aminosugars for 
detennination of Mur 
.j, 
Table 2 
.j, 
detennination of Mur 
according to 
- Hadzija (7) 
- Tipper (26) 
-!-
Table I 
final concentration of 0.2 M. The extract was incubated at room temperature for 2 h under 
rotation and was subsequently heated gradually in a waterbath to 100cC over a period of 30 min. 
The extract was centrifuged at 10,000 x g. The volume of the supematant was reduced by 
lyophilization to 25-50 ml and the extract was then centrifuged at 100,000 x g. 15 ml portions 
the supernatants were separated by gel filtration on a 275 ml gel bed of Sephadex 0-25 
(Pharnlacia, Sweden). Mur and protein was detennined in all fractions according to Hadzija [7] 
and Bradford [2]. The high molecular weight fraction was collected and loaded onto a Dowex 
50 IV x 4 column (Fluka, Switzerland) equilibrated in 0.1 M acetic buffer (pH 4.6) for further 
protein reduction. The volume of the pooled fractions was reduced by lyophilization to 10 011 and 
this preparation was dialyzed against I dm3 I M NaCI and followed thereafter against 3 x 3 dm3 
H20 (bid est). After centrifugation at 100,000 x g, the supematant was stored and used for 
determination of Mur (see below). This preparation is further referred to as A. For HPLC 
analysis of l\·lur a further removal of protein was necessary. Therefore, a DEAE sepharose CL-6B 
(Phannacia, Sweden) gel bcd of 22 ml was washed with 0.5 M NaCI followed by a large volume 
of H20. Then 5 ml of A was loaded onto the column and eluted with H20, until no more protein 
was detected. A 15 rul Mur containing fraction was collected after elution with 0.5 M NaCI. This 
15 1111 sample was dialyzed against H20, lyophilized and dissolved in 2 ml H20. This preparation 
is further referred to as B. In B Mur, protein and total carbohydrates [17] were determined. 
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Determination of Mur 
Preparation A: Mur was determined according to the method of Hadzija [7] with some 
modifications [9). In short: samples were hydrolyzed by heating for 2 h at 90'C with an equal 
volume of 5 M H2S04, then neutralized with 10 M NaOH. Hydrolyzed and unhydrolyzed 
samples (100 rl) were incubated with 50 rl I M NaOH at 36'C for 30 min. After the addition of 
I ml 18.8 M H2S04 (concentrated), samples were heated for 3.5 min at 100'C, rapidly cooled in 
ice, then mixed with 10 rl 0.16 M CuS045H20 in Hp and 20 rl 0.09 Mp-hydroxydiphenyl in 
ethanol. The blue color developed to a maximum in 30 min at 30oe. Absorbance at 570 nm was 
determined using a Titcrtek Multiskan (Flow Laboratories, Irvine, Scotland), Solutions containing 
0-100 llg muramic acid (Sigma, St. Louis, USA) per ml H20 were used as standards. The data 
are given as the difference in concentration between the hydrolyzed and non-hydrolyzed samples. 
In this way only Mur linked to the peptides in peptidoglycan is detennined and disturbing sugars 
like rhamnose and of course of lactic acid itself, which arc dctcnnined in the non~hydrolyzed 
sample, can be excluded. The presence of Mur in A was also determined by measurement of D~ 
lactic acid according to the method of Tipper [26). 2 ml of A was hydrolyzed with 2 ml 12 M 
HCI at 90'C for 2 h. The sample was lyophilized and dissolved in I ml H20. D-Iactate was 
detennined by enzymatic bioanalysis of D~lactic acid/lAactic acid (Boehringer Mannheim 
GmbH, Gemlany). 
Preparation B: The presence of Mur was determined with an amino acid aminosugar 
detemlination using High Perfomlancc Liquid Chromatography (HPLC) reversed phase tech~ 
niques according to Glauner [6]. In short: Dansylation of B: I ml was hydrolyzed with 500 IJI 12 
M HCL for three hours at 90°C. The sample was frozen, lyophilized and redissolved in 100 J-li 
H20. This sample was added to 1001t! 200 mM Borate buffer pH 8.8 and 100 It! 20 mM Dansyl 
chloride (5~Dimethylamino~naphthalene-l~sulfonyl chloride, Fluka Chemie AG, Swiss) in acetone 
and allowed to react for 2 h at 37°C. The reaction was stopped with 200 mM Phosphoric acid. 
Valine was used as an intemal standard and all other standard aminoacids (Sigma) underwent the 
same treatment. 
Separation of dansylated amino acids and aminosugars was accomplished by reversed 
phase HPLC. Samples were analyzed using a Pharmacia-LAB 2248 single pump solvent delivery 
system and VWM 2141 UV-VIS monitor both connected to a computer working with HPLC 
Manager software to control the pump, gradient mixer and UV-VIS detector operating at 330 11m. 
Integration and analysis of chromatograms was performed using the same software (Pharmacia, 
Sweden). Dansylated samples were separated using a Phammcia SuperPac Sephasil C 18, 5J.lm, 
4x250mm column. The flowrate used was 1 mVmin and the buffers used were A: 20 mM 
Sodiumphosphate pH 5.25 and butler B: 60% acetonitrile and 40% 50 mM Sodium phosphate pH 
4.0. At 0, 10, 16,21.5,22 and 27 min the % B was 30,50, 100, 100,30 and 30, respectively. 
Eluted products were detected at 330 nm, the wavelength which is maximally absorbed by 
the dansylgroups. Internal standard Valine and external standards Valine and Mur were used for 
calculating muramic acid contents of the spleen samples. 
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RESULTS 
Immunohistochemistry of the spleen 
Red pulp macrophages in the 6 spleens were immunohistochemically 
stained. figure 2 shows an immunohistochemic staining of a human spleen with 
monoclonal antibody 2E9 recognizing intestinal flora derived peptidoglycan 
polysaccharides. Another monoclonal antibody 2-4, recognizing MOP also 
stained cells in. these spleens (not shown). Negative control antibody NS7 of 
the same isotype, mouse IgG3, and with irrelevant specificity, did not stain the 
spleens. From these positive results we concluded that bacterial antigens were 
present in each of the spleens and that these could be used for isolation of a 
particular bacterial fl'action. 
Figure 2. lmmunohisloehemie staining with monoclonal 2E9 of human spleen. Three large 2E9 positive 
Olaerophages are stained black. Bar corresponds with 21.8 ~tnl. 
Purification of Mur fraction from spleen 
From all 6 spleens a preparation A was isolated according to the method 
described above in detail. The general outlines of the procedure are depicted in 
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figure I. figure 3 shows the elution pattern after sephadex G25 gelfiltration of 
the extracted spleen from patient I. Protein was found after an elution volume 
of 95 ml H20. Mur was detected after an elution volume of 85 ml H20 and 
increased to a maximum of 32 f.(g Mur per ml. Then it decreased and finally it 
sharply increased to a level much higher than 100 f.(g/ml. We pooled the 
fractions between 85 and 130 ml which represented a relatively high molecular 
weight fraction and discarded the low molecular weight fraction, because it 
contained lactate which disturbed the colorimetric Mur assay. The pool was 
loaded on a strong cation exchange column Dowex SOW x 4 which bound 90% 
of the protein. After Dowex the volume was reduced and the preparation 
dialyzed. In a pilot experiment samples of lysozyme solubilized cell wall 
fragments of EubacteriulII aerofaciens [22], a carbohydrate polymer with 20% 
(dry weight) Mur, were completely recovered in the corresponding fractions 
after the Sephadex G25 gel filtration and for 80% after the Dowex chromatogra-
phy. 
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Figure 3. Separation of high and low molecular weight fractions from human spleen extracts. Sephadex 025 
gel filtration of an extract of human spleen of patient I. In step 5 from fig. I 15 ml spleen extract was loaded onto a 275 
ml gelbed of a Sephadex 025 column and Mur and protein concentrations were determined in the fractions. 
From all spleens 10 ml preparation A was prepared. In A the protein 
concentration was still 0.5 to 1.5 mg/ml. The concentration Mur was deter-
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mined according to Hadzija with and without hydrolysis of the samples and the 
net values are given in Table I. Mur was also determined using D-Iactic acid 
dehydrogenase according to Tipper [26] and the table shows that in all prepara-
tions the concentrations determined with the colorimetric method were higher 
than found with the enzymatic method. Using E. aerofaciells cell wall frag-
ments we found twice as much Mur with the colorimetric method as compared 
to the enzymatic method of Tipper. Because both determinations of Mur are 
based on the presence of the lactyl group in Mur we felt that a completely 
different assay for Mur should be used to confirm the results. Therefore, HPLC 
analysis of Mur was employed. Since the method is based on a separation of 
dansylated amino acids and amino sugars, the preparation must be as free as 
possible from disturbing protein aminoacids. Therefore, the remains of prepara-
tion A from spleen I to 5 were fmiher purified by DEAE anion exchange. The 
E. aerofaciens cell wall polymers applied to the DEAE column showed that the 
protein Palt of the preparation was not bound. The Mur containing fraction, 
however, did bind and could be eluted from the column with 0.5 M NaCI. 
DEAE passage of preparation A reduced the protein contents considerably 
«200 Ilg/mi). 
Table I. Recovered Mur determined according to Hadzija (modified) and Tipper in 
preparation A from 6 human spleen extractions 
2 3 4 5 6 
Wet weight spleen (g) 91 70 55 93 57 73 
J..tmol Mur 
According to Hadzija 2.82 2.27 2.29 2.66 1.79 2.56 
According to Tipper 0.97 0.75 0.38 0.40 0.43 2.04 
In this sample, called preparation B, Mur, protein and total carbohydrate 
concentrations were determined with colorimetric assays and the results are 
shown in table 2. 
Samples of preparation B of spleen I to 5 were applied to HPLC. 
The strategy we used for Mur detection by HPLC was as follows: First, by 
adding a little dansylated muramic acid to the sample it was possible to spike a 
peak with a retention time of 11.3 min in the spleen sample as is depicted in 
figure 4A and B. There are many peaks in the chromatogram and therefore we 
decided to collect the peak with retention time 11.3 minutes and reanalyze this 
47 
Chapter 3 
peak to see if it really has the same retention time as the standard dansyl Mm. 
Indeed a major peak of the chromatogram of the collected peak had exactly the 
same retention time as dansyl Mur (see figure 4C and 0). Finally we deter-
mined Mur in the collected peak using the colorimetric assay according to 
Hadzija to complete the circle and prove that the spleen samples contain Mm. 
0.0 5 
E 
c 
~ 0.05 
co 
'" 
A 
j 
I~ 
I~WJ~ 
B j 
~1Ld)' IN\ , 
11.3min 
C I 
j 
L JlAAA 
0 j I 
, 
L ~ 1I 
11.3min 
Figure 4. Identification of Mur in preparation B from patient I. Reversed-phase HPLC on a CIS column (5J.lm, 4 
x 250 mm) in a discontinuous gradient of 0·15% Methanol over 27 minutes at 1.0 mllmin of A) Hydrolysed and 
dansylated preparation B of splcen extract from patient I. 8) Idem as A but spiked with dansyiatcd Mur. 
C) Collected peak with retention time 11.3 minutes from chromatogram A). D) Idem as C but spiked with dansylated 
Mur. Absorbance was measured at 330 nm. Peak with retention time 11.3 min identified as MUf, is indicated as -!.. 
Calculations of Mur concentration using valine as an internal standard 
gave results in the same range as the other method but may have been ham-
pered by contaminating protein amino acids (Table 2). If the results of Mur 
concentrations (Tables 1 and 2) are summarized as mean values they show that 
with HPLC 3.3 ,lIllOI, with Hadzija 1.9 ,1I1101 (8) and 2.4 /lmol (A), and with 
Tipper 0.8 /lmol per spleen (average 73 g) were found. 
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Table 2. Mur (pM), protein and totAl cAI'bohydrAtes (pg/ml) in preparation B from 5 
human spleen extractions 
2 3 4 5 
Mur: Hadzija 2.64 1.40 1.04 3.60 0.76 
Mur: HPLC 5.28 3.56 2.16 4.40 1.32 
Protein 564 352 412 368 780 
Carbohydrates 3320 2000 2000 5080 1240 
DISCUSSION 
Sen and Karnovsky found 100 pmol Mur per gram rat liver tissue and 
extracted muramyl compounds from brain and kidney [20]. A daily output of I 
Mmol of free diaminopimelic acid, an amino acid specific for muramyl pepti-
des, was found in human urine by Johannsen and Krueger [10]. Fox and Fox, 
however, could not detect Mur in human senllll and therefore considered the 
presence of peptidoglycan or Mur containing subunits a matter of dispute [5]. 
In this study we determined Mur in spleen tissue by three different methods. 
The spleen was chosen because a previous immunohistochemical study with 
monoclonal antibodies showed the presence of bacterial antigen in macrophages 
in the rat spleen [14]. The six human spleens used in this study also contained 
macrophages positively stained by monoclonal antibody 2E9. Specificity of the 
monoclonal antibody was checked by inhibition ELISA's and by inhibition of 
immunohistochemic staining of the spleens. Peptidoglycan polysaccharides were 
used as antigen. 
The isolation procedure was focussed on detecting Mur in polymeric 
peptidoglycan because that is the product which we think is present in the 
splenic macrophages based on our observations in rats injected with peptidogly-
can-polysaccharides from EubacteriulII aerojaciens [14]. Small muropeptide 
MDP administered in vivo in mice, however, is excreted unchanged in the 
urine within minutes [27]. The practical advantage of this assumption is that 
during the extraction and purification the low molecular weight fraction could 
be discarded. In this respect our study differed from the studies of Sen and 
Karnovsky [20] who were looking for low molecular weight muropeptides. 
Before and after homogenization of the spleen tissues, sterility was checked by 
cultivating the homogenate on a blood agar plate. No contamination could be 
detected. Acetic acid extraction was used to hydrolyse the Iysosomes in the 
spleen homogenates in which the peptidoglycan might be located [19]. After 
this, the aim was to remove as much protein as possible while keeping the 
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carbohydrate fraction. In the end we succeeded in isolating such a fraction 
containing a considerable amount of Mur. Mur was used as a marker for the 
presence of polymers of peptidoglycan because Mur is considered to be unique 
for peptidoglycan. 
We used three determination methods for Mul'. I) The method of 
Hadzija [7] (modified by Hazenberg et al. [9]) is based on the colorimetric 
determination of the lactyl group after acid hydrolyses to remove peptides in 
peptidoglycan and treatment with NaOH to hydrolyse the ether bond of the 
lactyl group in Mur. 
2) The method of Tipper [26]; D-Iactic acid is specific for bacteria 
[24] and the covalent ether bond of D-Iactic acid in Mur is very specific for 
this molecule and therefore for peptidoglycan. We adopted the method of 
Tipper in which lactate dehydrogenase is used for the detection of D-Iactic acid 
in peptidoglycan liberated after acid and alkali hydrolysis. Indeed D-Iactate was 
found in our EubacteriulII aerojaciens cell wall fragment preparation after 
consecutive acid and alkalic hydrolysis (data not shown). 
3) Because both methods for determination of Mur are based on 
detection of the (D) lactyl group a third method not dependent on the presence 
of lactic acid was used. The HPLC analysis of amino sugars were carried out 
according to a modified procedure developed by Glauner [6] who studied the 
composition of peptidoglycan of Escherichia coli extensively. After collection 
of the peaks with a retention time of 11.3 min (figure 4), we were able to 
determine Mur in this fraction with the Hazija method. We conclude that in the 
human spleen Mill' and therefore peptidoglycan is present, not as small mura-
myl-peptides as was previously looked for, but as larger molecules probably 
stored in spleen macrophages. 
Peptidoglycan has many biological effects in vivo, like sleep induc-
tion [16], complement activation [30], adjuvant activity [4] and many other 
immunostimulatOlY effects like antibody production [28] and T cell mediated 
arthritis induction [8,21,22,23,13]. In vitro peptidoglycans are able to stimulate 
human monocytes to produce TNFa and II-I and inhibition or activation of 
monocyte migration [25,18]. From the results presented in this paper and 
results from other investigators it can be concluded that our body tissues are 
continuously exposed to these bacterial products which in some cases might 
lead to biological activities in vivo. If so, this in its turn might provide a clue 
to inflammation with unknown etiology, like rheumatoid althritis and reactive 
arthritis. Presently we are investigating the biological properties of this peptido-
glycan. 
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ABSTRACT 
N-Acetylmuramyl-L-alanine amidase (EC 3.5.1.28) cleaves the amide 
bond between N-acetyl muramic acid and L-alanine in the peptide side chain of 
different peptidoglycan products. The enzyme was purified from human plasma 
using a three step column chromatography procedure. Monoclonal antibodies 
were produced against the purified human enzyme. By coupling of a high 
affinity monoclonal antibody to sepharose beads an immunoadsorbent column 
was prepared. Using this second purification method it was possible to purify 
large amounts of the amidase from human plasma in a single step. SOS-PAGE 
showed one single band of 70 kOa and two-dimensional electrophoresis showed 
the presence of multiple isomeric forms of the protein with pI between 6.5 and 
7.9. Two different methods were used for determination of substrate specificity, 
a HPLC method separating peptidoglycan monomers from the reaction products 
after incubation with amidase and a colorimetric method when high molecular 
weight peptidoglycan was used as a substrate for amidase. It is shown that the 
disaccharide tetra peptide, disaccharide penta peptide and the anhydro disaccha-
ride tetrapeptide are good substrates for the amidase and that muramyl dipep-
tide and disaccharide dipeptide are not a substrate for the amidase. Using one 
of the monoclonal antibodies against the amidase it was shown in FACScan 
analysis that N-acetylmuramyl-L-alanine amidase is present in granulocytes but 
not in monocytes from unstimulated peripheral blood of a healthy donor. The 
presence of N-acetylmuramyl-L-alanine amidase in granulocytes is a novel 
finding and perhaps important for the inactivation of biologically active 
peptidoglycan products still present after hydrolysis by lysozyme. 
INTRODUCTION 
Peptidoglycan polymers, oligomers and monomers have potent biological 
effects. An important factor in the induction of the biological effects is the 
ability of the peptidoglycan products to persist in human tissues. Bacterial cell 
wall products can be degraded by 3 different human enzymes: lysozyme (l], 13-
N-acetylglucosaminidase [2] and the not well characterised N-acetylmuramyl-L-
alanine amidase (NAMLAA). This NAMLAA hydrolyses peptidoglycan by 
cleaving the lactamide bond between N-acetyl muramic acid and L-alanine in 
the peptide side chain of the peptidoglycan molecule. Bordetella pertussis 
tracheal cytotoxin is an anhydro-disaccharide tetrapeptide peptidoglycan 
monomer which is capable of reproducing the respiratory cytopathology 
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observed during peliussis [3, 4]. NAMLAA is able to degrade this anhydro 
monomer very rapidly in vitro and might be the most important enzyme 
involved in the degradation of the tracheal cytotoxin in vivo. We hypothesize 
that this amidase, which we found in all human sera tested until now [5], plays 
an impOliant role in the degradation and inactivation of biologically active 
peptidoglycan polymers and monomers in human tissue. 
Amidase (NAMLAA) activity in human serum was first described by 
Ladesi6 et al. in 1981 [6] One year later Valinger et al. from the same group 
partially purified NAMLAA from human and mouse serum and defined its 
enzymatic activity [7]. In the present study we describe two methods for the 
purification of NAMLAA from human plasma. The first method is based on 
DEAE, heparin sepharose and hydroxylapatite column chromatography. The 
protein obtained by this three-step method was used to raise monoclonal 
antibodies against the enzyme. With these antibodies an immunoadsorbent 
affinity column was prepared with which amidase was purified in one single 
step with a 36% yield of the enzymatic activity. 
MATERIAL AND METHODS 
Purification of NAMLAA with three-step procedure 
300 011 human plasma was dialyzed 3 times against 2 L 25 mM sodium phosphate buffer 
pH 7.5. After dialysis it was centrifuged for 15 min at 20,000 x g. The supernatant was then 
loaded onto a 500 1111 DEAE sepharose 4B (Phannacia) column. The column was washed with 8 
L 25 mM sodium phosphate buffer pH 7.5 until no more protein could be eluted. Elution of the 
amidase containing fraction was performed by changing the buffer to a 25 mM sodium phosphate 
buffer with 0.5 M NaC!. Amidase-containing fractions were pooled and dialyzed 3 times against 
25 mM sodium phosphate buffer pH 7.5 and loaded onto a 50 011 heparin sepharose CI-4B 
column (Phannacia). The column was washed with 10 column volumes of the sodium phosphate 
buffer until the eluate did not contain any protein. Elution was perfonned using a linear gradient 
of 300 ml sodium phosphate pH 7.5 with 300 ml sodium phosphate pH 7.5 with 0.25 M NaCI. 
Amidase-containing fractions were pooled and dialyzed 3 times against 2 L 25 mM sodium 
phosphate pH 6.8 and loaded onto a 15 ml hydroxylapatite (Biorad) column. Amidase does not 
bind to this column. The flow through was collected and dialyzed against 20 mM 
NH4HC03 pH 8.0. All steps were perfonned in a cold room (4"C). The NAMLAA activity in 
the samples was detcnnined using the colorimetric assay described below. 
Peptidoglycan substrates 
Peptidoglycan monomers from Brevibacterillm divaricatllm (ATCC 14020) GlcNAc-
MurNAc·L-Ala-D·isoGln·m·Dpm]·(D)·amide-(L)·D·Ala·D-Ala pentapeptide, and GlcNAc-
MurNAc-L-Ala-D-isoGln-m-Dpm-D-Ala tetrapeptide were prepared as described by Hazenberg 
and de Visser [5]. 
MurNAc-L·Ala·D·isoGlu (MDP) (Sigma), GlcNAc·MurNAc-L-Ala·D·isoGlu (GMDP) 
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(Calbiochem corp), GlcNAc-MurNAc-anhydro-L-Ala-D-Glu-m-Dpm-D-Ala (anhydro disacchari-
de-tetrapeptide) isolated from Escherichia coli was a kind gift from A. Dijkstra, Hoffman La 
Roche. 
Escherichia cot;, Brevibacterium divaricalum, Eubacterium aero/aciel1s, Bifidobacterium 
adolescentis and Streptococclls pyogenes peptidoglycans were prepared according to Severijnen et 
al. [8]. lvlicrococcllS lysodeikticus was obtained from Sigma. The polymeric peptidoglycans were 
degraded by incubating 250 ~g/ml overnight with a 25 ~g/ml lysozyme solution in 10 mM 
sodium acetate buffer pH 5.6. Peptidoglycan concentrations vary between different experiments. 
Detection of NAMLAA activity by a colorimetric method 
Amidase activity was detennined as described by Hazenberg and de Visser [5] with some 
modifications. The method is based on detennination of the increase of a free lactyl group in the 
peptidoglycan substrate due to the removal of the peptide side chain. Peptidoglycan monomers 
from Brevibacterillm divaricatlll1l (ATCC 14020) were used as a substrate. 200 j..tl amidase 
sample and 200 ~I substrate diluted in 20 mM NH4HC03 pH 8.0 to a final concentration of 500 j..tg muramic acid/ml were incubated for 15 minutes at 37°C. The reaction was stopped by adding 
200 ~I 1M NaOH and incubating for 30 min. at 37°C. For detennination of background, 
substrate was incubated with buffer for 15 min at 37°C, In these samples muramic acid was 
detennined as follows. 100 ~I sample + I ml (conc) H2S04 was boiled for 3.5 min and rapidly 
cooled in icewater. Then 10 ~'I 0.16 M CuS04.5H20 and 20 ~I 0.09 M p-hydroxydiphenyl in 
ethanol were added. After a 30 min incubation period at 30°C the absorbance at 570 nm was 
measured using a Titertek Multiskan (Flow Lab. Irvine, Scotland). 0-100 ~g/ml muramic acid 
solutions were used as standards. For detennining the specific activity of NAMLAA using 
polymeric peptidoglycan lower concentrations of peptidoglycan were used. 
Detection of NAMLAA activity by HPLC 
Substrate specificity was detennined using Brevibaclerium divaricalum GlucNAc-
MurNAc-pentapeptide and tetrapeptide. Also MurNAc-L-Ala-D-isoGlu (MDP), GlcNAc-
MurNAc-L-Ala-D-isoGiu (GMDP) (Calbiochem corp), GlucNAc-MurNAc[anhydro] tetrapeptide 
isolated from E. coli were used. 500 j..tglml samples were incubated with affinity-purified amidase 
in a final concentration of 1 /.tg/ml 25 mM NH4HC03 buffer pH 8.0 at 37°C, For determination 
of the background the substrate was incubated with buffer. The reactions were stopped after 15 
min by diluting the samples 10 times with 25 mM sodium phosphate pH 3.5 (HPLC buffer A). 
Peak areas were used to calculate the enzymatic activity. 1 Unit is defined as the amount of 
substrate (~mol) hydrolysed per minute at pH 8.0, 37°C. 
Reversed phase HPLC was used for separation of the reaction products. to j..tl samples 
were analyzed using a Phannacia-LKB 2248 single pump solvent delivery system and VWM 
2141 UV-VIS monitor both connected to a computer working wilh HPLC manager software to 
control the pump, gradient mixer and UV-VIS detector operating at 205 nm. Integration and 
analysis of chromatograms was perfonned using the same software (Phamlacia, Sweden). The 
samples were separated using a Phannacia Superfac Sephasil C18, 5j..tm, 4 x 250 mm column. 
The flowrate was I mVmin and the buffers were A: 25 mM sodium phosphate pH 3.50; B: 15% 
methanol in 25 mM sodium phosphate pH 4.70. At 0, 2, 10, 12.5, 13, 15 min the percentage B 
was 0, 0, 100, 100, 0, 0 respectively. 
For determination of Km and maximal rate of catalysis (V max), substrate concentrations 
were used between 2 mM and O. I mM GlucNac-MurNAc-pentapeptide of Brevibacterium 
divaricatum. The arninoacid and aminosugar composition of the separated peaks before and after 
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amidase incubation was detennined according to the method described in a previous paper [9], 
Preparation of monoclonal antibodies 
The purified amidase was used for preparing monoclonal antibodies. A male Balb/c 
mouse was injected intraperitoneally with 50 J.lg of NAMLAA in complete Freund's adjuvant. 
After 6 weeks the mouse received a booster of to J.lg NAMLAA in incomplete Freund's 
adjuvant. After another 6 weeks the mouse received a second booster of 10 J.tg amidase in 
incomplete Freund's adjuvant, intraperitoneally and 10 J.lg amidase in PBS, intravenously. Three 
days later, the mouse was sacrificed and cells isolated from popliteal, inguinal and axillary 
Iymphnodes and the spleen were fused with the Sp2/0 plasmacytoma cell line in a ratio of 5:1 
and 5:2 (spleen: Sp21O) ~sing standard procedures for the production of hybridomas [13]. Cells 
were seeded at a concentration of 8.10 cells/well in the presence of human growth factor (40 
Vim I) [II]. The supernatants of 3000 wells were tested for the production of antibodies against 
amidase in an ELISA. The amidase-positive supernatants were tested in an isotype ELISA [12]. 
Only IgG-producing clones were used for further experiments. Monoclonal antibody AAA4 
showed the highest affinity for NAMLAA and was used for preparing a FITC-Iabeled mono-
clonal antibody (a-NAMLAA-FITC) and for preparing an imrnunoadsorbent column. 
Preparing immunoadsorbent column and purification of NAMLAA 
Monoclonal antibodies were purified over a 10 ml Immunopure Immobilized Protein G 
column (Pierce) using the standard protocol of the supplier. 7.2 mg of monoclonal antibody 
AAA4 was dialyzed 3 times against 2 I 0.1 M NaHC03 + 0.5 M NaCI and coupled to 2 g CNBr-
activated Sepharose 4B (Phannacia LKB Biotechnology) according to the protocol of the 
supplier. Human plasma (obtained from the blood bank Rotterdam) was dialyzed against PBS and 
diluted 2 times in PBS before it was loaded onto the column. The column was washed with PBS 
until no more protein was detected in the eluate. The amidase was eluted by changing the buffer 
to 0.1 M Gly.HCI pH 3.0. The peak fractions were immediately dialyzed against 20 rnM 
NH4HC03 pH 8.0. 
Immunofluorescence labeling, flow-cytometric analysis 
Labeling of AAA4 with fluorescent isothiocyanate (FITC) was perfonned according to 
standard procedures [13]. Human peripheral blood cells were stained for intracellular antigens 
according to SyrjilH [14]. In short: 100 ~I citrate blood was lysed and fixed by adding 2 011 of 
F ACS lysing solution (Becton Dickinson) and incubating for 10 min at room temperature. The 
cells were centrifuged and washed 2 times with PBS + 0.5% BSA. Then the mouse a-NAML-
AA-F1TC or rabbit a-human lysozyme (DAKO, ITK Diagnostics) were added and the mixture 
was incubated for 10 min at room temperature. The cells were washed 2 times with 2 ml PBS-
BSA. The rabbit a-lysozyme-treated cells were incubated with the second antibody goat~a-rabbit~ 
FITC for 10 min, washed 2 times with PBS-BSA and finally resuspended in 200 ~I F ACS flow 
(Becton Dickinson). The analyses were perfonned with a FACScan cytofluorimeter (Becton 
Dickinson, Sunnyval, CAl. 
SDS-Polyacrylamide gel electrophoresis and immunoblot analysis 
The amidase was subjected to 10% 80S-PAGE to check for purity. Affinity-purified 
amidase samples of 20 ~I were boiled for 3 min together with 5 ~I loading buffer (60 mM Tris. 
HCI pH 6.8; 23% glycerol 3% SDS; 0.06% bromophenol blue; 10% p-mercapto ethanol) I 0 ~,I 
of these samples were analyzed on 10% SDS-PAGE (Mini Protein, BioRad). Samples were 
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visualized by Coomassie Blue staining or transferred to nitrocellulose in 25 mM Tris, 190 mM 
glycine and 20% methanol transfer buffer. Nitrocellulose sheets were blocked in low-fat milk for 
30 minutes and subsequently washed three times with 0.5% Tween-20 in PBS. Nitrocellulose 
sheets were then incubated for 1 hour with monoclonal antibodies 500 times diluted in PBS-
Tween at room temperature. Following three washes, goat anti-mouse IgG conjugated to alkaline 
phosphatase (TAGO) was added in a 1000 times dilution and incubated for [ hour at room 
temperature. The blot was washed three times with PBS-Tween and then three times with PBS. 
For visualization of antibody-antigen complexes the alkaline phosphatase substrate, nitro blue 
tetrazolium/5-bromo-4-chloro indoxyl phosphate (NBTIBClP), was used as described [20]. 
Two-dimensional electrophoresis 
25 III of affinity-purified NAMLAA was mixed with 25 III sample buffer (0.3% SDS, 
200 mM dithiothreitol, 28 mM Tris.HCI and 22 mM Tris-base) and heated for 4 min at 100'C, 
Two-dimensional electrophoresis was perfonned with the Millipore Investigator system. We used 
ampholytes with a pH range from 3-10 for the first dimension. For the second dimension we 
used [0% Duracry[ gels. Glyceraldehyde-3-phosphate dehydrogenase carbamalytes (Phannacia) 
were used as iso-electric-focussing markers. Proteins were visualized with a silver staining 
technique. All steps were perfonned according to the manufacturers' instructions. 
Gel permeation chromatography 
A superdex 200 HR 10/30 column with 10 mm internal bore diameter and 30 em length 
(Vc=24 ml) was used (Phannacia). The column was connected to a standard FPLC system 
(Phannacia), consisting of a LCC chromatography controller, two P-500 pumps, a MV -7 injector 
with a 200 J.l.1 sample loop, a UV-l monitor at 280 nM operating at 0.05 AUFS sensitivity and a 
FRAC 100 fraction collector. Routinely, isocratic elution with PBS was used. Column selectivity 
was detemlined by using mixtures of molecular weight marker proteins (Phannacia) ranging from 
670 kDa to 17 kDa. 200 ~I purified 
NAMLAA was injected on the column. Enzymatic activity was detennined in the peak fractions. 
1m m u noh istochem istry 
Blood smears of a healthy person were fixed for 10 minutes in acetone. After rinsing in 
PBS with 0.2% bovine serum albumin (BSA), the smears were incubated for 1 hour at room 
temperature with monoclonal antibody AAA3 (diluted 40 Ilg/ml in PBS-BSA) or, for control 
staining, an irrelevant monoclonal antibody of the same isotype and concentration. Subsequently, 
the smears were rinsed in PBS-BSA and incubated for 30 minutes at room temperature with 
rabbit anti-mouse immunoglobulin (Z259, Dakopatts) diluted 1:20 in PBS-BSA with 1% nonnal 
human serum. After rinsing in PBS-BSA, a I :40 dilution of alkaline phosphatase-mouse-anti-
alkaline phosphatase complex (APAAP, D651, Dakopatts, Denmark) was applied for 30 minutes. 
To develop the stain the smears were incubated for 30 minutes at room temperature with new 
Fuchsin substrate (Chroma), which stained positive cells red. After rinsing in distilled water the 
nuclei of the cells were stained blue by incubation for I minute with hematoxylin and rinsing in 
fresh water for 10 minutes. Finally, the smears were mounted in Kaiser's glycerol gelatin 
(Merck). 
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RESULTS 
Purification of NAMLAA from human plasma 
Table 1 shows the purification scheme of the three step purification. The 
amidase activity in dialyzed and centrifuged plasma was 46 mU per mg protein. 
The final pure amidase had a specific activity of 6.7 U per mg protein. Most of 
the total activity was lost during this purification procedure (99%). Starting 
with 300 ml plasma it was possible to purity about I mg NAMLAA using this 
method. 
Table 1. Purification of N-acetylmuramyl-L-alanine amidase from human plasma by three-
step procedure 
protein cone total protein specific activity Yield 
(mg/ml) (mg) (Ulmg) (%) 
plasma 48.7 15.6 x 103 4.6 x 10-2 100 
DEAE 13.6 2.7 x 102 0.11 41 
Heparin 0.2 15.4 3.2 6.9 
Hydroxylapatite 1.0 x 10-2 1.0 6.7 0.9 
Protein concentrations were determined according to the method of Bradford. Enzymatic activity 
was dctcnnined by the colorimetric assay. 
Monoclonal antibodies and immunoaffinity purification 
Six different monoclonal antibodies against NAMLAA were obtained. 
Monoclonal AAA4 showed the highest affinity for the human amidase in a 
competition ELISA (not shown) and was therefore used to prepare an immuno-
adsorbent column. 7.2 mg purified monoclonal antibody was coupled to CNBr-
activated sepharose beads. The capacity of the column was sufficient for the 50 
ml plasma used. No amidase activity could be detected in the flow-through 
when diluted plasma was applied to the column. After elution with 0.1 M 
Gly.HCI pH 3.0, plll'e amidase was eluted fi'om the column. From 50 ml 
plasma it was possible to obtain 0.6 mg pure amidase. 
Table 2 shows the purification scheme. The amidase activity in this 
dialyzed and centrifugated plasma was 31 mU/mg protein, determined by the 
HPLC method. The purified amidase solution obtained by this method con-
tained a specific activity of 46 U/mg protein and 36% of the enzymatic activity 
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was recovered. Therefore, by using the immunoadsorbent column it was 
possible to increase the yield 38-fold and the final product had a specific 
activity 6.9-fold higher compared with the three-step procedure. 
Table 2. Purification of N-acetylmuramyl-L-alanine amidase from human plasma by 
immunoaffinity chromatography 
Protein cone Total protein 
(mgtml) (mg) 
plasma 48.7 2435 
Irnmunoaffinity 0.1 0.6 
Specific activity 
(U/mg) 
3.1 x 10-2 
46 
Yield 
(%) 
100 
34 
Protein concentrations were detemlined according to the method of Bradford. Enzymatic activity 
was detemlined by the HPLC method. 
SDS-Polyacrylamide gel electrophoresis and immunoblot analysis 
Figure I shows a 10% SOS-PAGE. Purified amidase is electrophoresed 
as a single band with a molecular mass of 70 kOa. After deglycosylation by N-
glycosidase-F digestion, the molecular mass decreased to 60 kOa (not shown). 
Western blot analysis of purified NAMLAA before and after deglycosyl-
ation showed that foul' of the six monoclonal antibodies including AAA4, the 
antibody used for purification, were able to recognize NAMLAA in both forms. 
Two-dimensional electrophoresis 
Figure 2 shows affinity-purified NAMLAA subjected to iso-electro-
focussing in the first dimension and 10% polyacrylamide gel electrophoresis in 
the second dimension. At least 8 different isomeric forms are visible of this 
glycoprotein. The pI values vary between 7.0 and 7.9 although the main spots 
are in the 7.5-7.8 range. No impurities are visible after silverstaining. 
Detection of NAMLAA activity by HPLC 
NAMLAA activity was tested with different peptidoglycan products. 
Muramyl dipeptide (MOP) was tested because this product is the smallest 
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Fig I. Polyacrylamide gel electrophoreses of purified N-acctylmuramyl-L-alanine-amidase. 10 J.tI samples of three 
different concentrations were analyzed on 10% PAGE-SDS. Lane I is amidase purified using the three-step procedure. 
Lane 2 and 6 are molecular weight markers and lane 3, 4 and 5 are 20, 40 and 100 JIglml dilutions (resp.) of 
immunoaffinily-purified amidase. NAMLAA is clearly shown as a single band of 70 kDa. The gels were stained with 
Coomassie Blue. 
component of peptidoglycan known to posses biological activity. Harrison and 
Fox [15] described that MDP was degraded by human serum. We did not find 
this activity for the purified amidase. N-acetylglucosamine-N-acetylmuramic 
acid di-peptide (GMDP) was not a substrate for NAMLAA either. Di-saccha-
ride tetrapeptide and the anhydro-disaccharide tetrapeptide were good substrates 
for NAMLAA. The allhydro form was degraded four times slower than the 
llon-anhydro disaccharide-tetrapeptide. The disaccharide-pentapeptide was 
degraded at the same velocity as the tetrapeptide, as determined by HPLC 
analysis (Figure 3). 
Using the BrevibacteriulII divaricatul11 disaccharide pentapeptide as a 
substrate the maximal rate of catalysis is 0.1 0 mmoVmin and the Km value is 
2.5 mM. 
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Fig 2. Two·dimenslonal electrophoresis of afflnity-purilied NAMLAA. First dimension isoelectrofocussing in a pH 
range of 3·10 and second dimension 10% Duracryl electrophoresis separation on molecular weight. Thirteen different 
isomeric forms of the glycoprotein are visible. The silverstained gel does not show any impurities. 
Detection of NAMLAA activity by colorimetric assay 
Six different lysozyme-solubilized peptidoglycan samples were incubated 
with NAMLAA. In Table 3 the differences in the peptide bridges of the 
peptidoglycans are shown with the corresponding specific activity of 
NAMLAA. B. ado/escentis, S. pyogenes and M /ysodeikticlls peptidoglycans 
are not degraded by NAMLAA. The substrate concentration was 350 J.lg/ml 
based on the concentration muramic acid in the reaction mixture. 
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Fig J. Rc\'crsed phase high performance liquid chromatography chromatogram of Brel.'lbacterilllll dll'ar/catltlll 
disaccharide pentapeptide before (A) and afler (B) incubation with NAMLAA. The large peak with retention time 
12.8 min in A represents the disaccharide pentapeptide. The small peak with retention time 11.8 min is the disaccharide 
tetrapeptide. The large peak in B with retention time 2.8 min (void volume) contains the peptide product released from 
the sugar moiety. The small peak at 5 min contains the disaccharide. The difference in area of the peaks in A with the 
corresponding peaks in B is a direct measure for the amount of substrate 
degraded by NAMLAA. 
Flow-cytometric analysis 
FACScan analysis of the nucleated cells from blood of a healthy donor 
were performed to determine if NAMLAA is produced by white blood cells, In 
Figure 4 it is shown that granulocytes contain NAMLAA but monocytes do 
not. Lysozyme could be detected in both monocytes and granulocytes (not 
shown), PBS and IgG-FiTC were used as a negative control (Figure 4A and 
4B), 
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Fig 4. FACScan analysis of nucleated fraclion from blood of a healthy donor. Based on sideward scatter human 
peripheral blood cell suspensions can be divided in three different populations. The lower population consists of 
lymphocytes, the middle population consists of monocytes and de upper population are the granulocytes. GranuloC}1es are 
positively stained by a-NAMLAA-FITC (C), monocytes and lymphoc}1eS are not stained with this monoclonal antibody. 
PBS (A) and IgG-FlTC (B) were used as negative controls. 
Native molecular mass determination 
The selectivity curve used was: KA V = 2.309 - 0.378 log Mr 
Ve - Vo Ve - 8 
KAV where Ve is the elution volume 
Vt - Vo 12,8 Vo is void volume (8.0 ml) 
Vt is total volume (20.7 ml) 
The elution volume of the NAMLAA activity containing peak was 14.0 ml. 
Therefore the calculated molecular mass is 69 kDa ± \0%, Which proves that 
the amidase is composed of one subunit. 
Immunohistochemistry 
The immunohistochemical staining of the blood smears of a healthy 
person with monoclonal antibody AAA3 showed a positive staining of the 
granulocytes, The mononuclear cells including monocytes were negative. No 
positive cells were found by using an irrelevant monoclonal antibody with the 
same isotype and concentration. 
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Table 3. NAMLAA activity related to difference, in peptide bridge, in peptidoglycan from 
6 bacterial species 
Peptidoglycan Source Aminoacid, in peptidc bridge 
E. coli 
B. dival'icatllm 
E. aerofaciens 
B. adolescentis 
S. pyogenes 
D·Ala 
, 
, 
NAM-L-Ala-D-Glu-M-Dpm-
D-Ala , 
, 
NAM-L-Ala-D-isoGln-M-Dpm-
D-Ala 
, 
, 
NAM-L-Ala-D-Glu-L-Lys-
D-Ala 
, 
, 
NAM-L-Ala-D.Glu-L-Om-Ala-D-Asp·D-Ser-
D-Ala 
, 
, 
NAM-L-Ala-D-Glu-L-Lys-D-Ala-L-Thr-L-Ala-
Specific activity (U1mg) 
57 
III 
12.5 
2 
o 
M. iysodeiklicliS NAM-L-Ala-D-Glu-L-Lys-D-Ala-L-Lys-D-Glu-L-Ala- o , , 
, , 
Gly Gly 
Enzymatic activity was dctermined with the colorimetric method. 
DISCUSSION 
In 1990 Vanderwinkel et al published the purification of NAMLAA from 
human serum [16]. They found an enzyme of Mr 120.000-130.000 in native 
PAGE and two bands of 57 kDa and 70 kDa under denaturating conditions and 
considered amidase to be a dimeric protein with pI of 4.5-5.5. They also found 
the E. coli-derived MurNAc-tripeptide to be a good substrate for the enzyme as 
well as some polymeric peptidoglycans. Because it was only possible to purify 
very small amounts of amidase with their method and the propeliies of the 
enzyme did not always correspond with the protein we were purifying we 
started with the development of a large scale purification to make a good 
characterization of the enzyme possible. 
This study describes two methods for the purification of NAMLAA from 
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human plasma. The purification with a NAMLAA specific immunoabsorbent 
column yielded a higher specific activity than the three-step column purification 
method. Apparently some of the amidase purified by the three-step method 
loses some of its activity during the different steps, because the specific activity 
is much lower compared to the immunoaffinity-purified NAMLAA. Purification 
of human NAMLAA can therefore best be carried out using the specific 
immunoabsorbent column. It is unknown if all the immunoaffinity-purified 
NAMLAA is still active. It is therefore not possible to determine exactly the 
concentration of NAMLAA in plasma, but it must be at least 10 ~lg/ml plasma. 
This is similar to normal serum concentrations of lysozyme which varies from 
7 to 20 J.lgfml [I]. 
The pattern of dots obtained after two-dimensional electrophoresis indicates 
that the NAMLAA contains variable amounts of charged groups. [t was shown 
that NAMLAA is a glycoprotein because the molecular mass decreased after 
incubating the enzyme with N-glycosidase F. This was confirmed by experi-
ments where to some extent NAMLAA activity bound to Sambuccus Nigra 
Agglutinin (SNA) coupled to sepharose beads (results not shown). SNA has a 
specific affinity for a-NeuNAc [2-6] GalNAc [17] which is a charged group. 
Enzymatic activity of the enzyme is not restricted to peptidoglycan 
monomers. After lysozyme degradation, polymers with molecular mass greater 
than 106 Da from E. coli and E. aerofaciens were degraded for more than 80% 
depending on NAMLAA concentration and reaction time. The composition of 
the peptide side chains of these substrates differ widely staliing fi·om the third 
aminoacid, counted from MurNAc (Table 3). Therefore it seems obvious that 
the first three aminoacids together with N-acetylmuramic acid are the most 
important in determining substrate specificity. After alkali hydrolysis of the N-
acetylgroup of N-acetylmuramic acid, the remaining glycopeptide is no longer 
degradable by NAMLAA. 
The six purified monoclonal antibodies against NAMLAA all have differ-
ent affinities for amidase. 3 out of 6 recognize NAMLAA in Western blot (data 
not shown). Flow-cytometric analysis of blood using a FITC-Iabeled mono-
clonal antibody against NAMLAA showed that granulocytes contain NAM-
LAA. This to our knowledge novel finding makes it very likely that the 
enzyme is involved in degrading peptidoglycan products in blood and tissues, 
which could be liberated during infections or absorbed from the gut. The 
monoclonal antibodies are currently being used to screen a human cDNA 
expression library in order to identify the gene coding for the enzyme. 
Peptidoglycan is a polymer found in all bacterial cell walls. Biological 
activities of peptidoglycan are multi fold. It has many biological effects in 
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common with LPS but it is also able to cause chronic inflammation [18). 
Peptidoglycan monomer anhydromuramyl dipeptide possesses sleep-inducing 
capacity [19). All these biological activities of peptidoglycan monomers/poly-
mers are likely to be susceptible to degradation by amidase. Further research 
will be done to study the influence of amidase on the biological activities of 
peptidoglycan. The relatively simple method described in this paper for 
obtaining large amounts of pure NAMLAA will make it possible to study this 
human enzyme in greater detail. 
REFERENCES 
I. Jolles, P. and Jolles, J. (1984) Mol. Cell. l3iochem. 63. 165-189. 
2. Striker. R.. Kline. M.E., Haak, R.A., Rest, R.F., and Rosenthal, R.S. (1987) Infect. Immun. 
55, 2579-2584. 
3. Cookson, B.T., Cho, H.-L., Herwaldt, L.A. and Goldman, W.E. (1989) Infect. Immun. 57, 
2223-2229. 
4. Luker, K.E .• Collicr, J.L., Kolodziej, E.W., Marshall, G.R. and Goldman, W.E. (1993) 
Proc. Natl. Acad. Sci USA 90, 2365-2369. 
5. Hazenberg, M.P. and de Visser, H. (1992) Eur. J. Clin. Chem. Clin. Biochem. 30, 141-144. 
6. Ladesic, B., Tomasic, J., Kveder, S., and Hrsac, l. (1981) Biochem. Biophys Acta 678, 12-
17. 
7. Valinger, Z, Ladesic, B. and Tomasic, J. (1982) Biochem. Biophys Acta 701, 63-71. 
8. Severijnen, AJ., van Kleef, R., Hazenberg, M.P., and van de Merwe, J.P. (1989) 1. 
Rheumatol. 16, 1061-1068. 
9. Haijer, M.A., Melief, M.J., van Heiden-Meeuwsen, e.G., Eulderink, F., and Hazenberg, 
M.P. 
(1995) Infect. Immun. 63, No 5, 1652-1657 
10. Shulman, M., Wilde, C.D., and Kohler, GA (1978) Nature 276, 269-270. 
I!. Aarden, C., Lansdorp, P and de Groot, E. (1985) Lymphok 10, 175-185. 
12. Bos, N.A., Kimura, H, Meeuwsen, C.G., et al. (1989) Eur. J. Immunol. 19,2335-2339. 
13. Coligan, J.E., Kmisbeek, A.M., Margulies, D.H., Shevach, E.M., and Stober, W. (1990) 
Current protocols in immunology Green Publishing Associates and John Wiley & Sons, 
inc., 3.5-3.6. 
14. SyrjilH, M.T., Tiirikainen, M, Sansson, S.E., and Krusius, T. (1993) Am. J. Clin Pathol. 99, 
298-303. 
15. Harrison, J. and Fox, A. (1985) Infect. Immun. 50,320-321. 
J6. Vanderwinkel, E., De Vlieghere, M., De Pauw, p" Cattalini, N., Ledoux, V" Gigot, G. and 
Ten Have, J-P. (1990) Biochem. Biophys. Acta 1039, 331-338. 
17. Shibuya, N., Goldstein, I.J., Van Damme, E.I.M. and Peumans, W.I. (1988) J. BioI. Chem. 
262, 1596-1601. 
18. Cromartie, W.I., Craddock, J.G., Schwab, S.K. and Yang, C.H. (1977) J. Exp. Med. 146, 
1585-1602. 
19. Krueger, J.M., Pappenheimer, J.R. and Kamowsky, M.L. (1982) J. BioI. Chem. 257, 1664-
1669. 
20. Blake, M.S., Johnston, K.H., Russell-Jones, G.I., Gotshlich, E.C. (1984) Anal. Biochem. 
136, 175-179. 
68 
of 
:;alli\:U after 
an 
amidase 
Maarten A. Hoijer, Marie-Jose ~~11ef, Reno Debets, 
.. al1.4~¥aarten P. Hazeilberg 
Department oj Immunology, Erasmus University, 
Rotterdam, The Netherlands 

Illactivatioll of PG by NAMLAA 
ABSTRACT 
N-Acetylmuramyl-L-alanine amidase (EC 3.5.1.28) purified from human 
plasma, cleaves the amide bond between N-acetyl muramic acid and L-alanine 
in the peptide side chain of peptidoglycan, an impOltant component of bacterial 
cell walls. In humans, peptidoglycan can be degraded by lysozyme, N-acetyl-
glucosaminidase and N-acetylmuramyl-L-alanine amidase. The biological 
activity of different peptidoglycan digests was investigated using two properties 
of peptidoglycan: the capability to induce atthritis in Lewis rats and the 
capability to induce the release of the inflammatory cytokines IL-I, IL-6 and 
TNF-a in vivo and in vitro. The results show that only after lysozyme and 
amidase treatment the peptidoglycan 11'OIn EubacteriulIl aerojaciells was unable 
to induce arthritis in Lewis rats. IL-I, IL-6 and TNF-a production in mice after 
intravenous injection of cell wall fragments was lower after in vitro degradation 
of the cell wall fragments by amidase. These in vivo results were confirmed in 
human monocyte cultures and whole blood assays. 
We postulate that degradation of peptidoglycan by N-acetylmuramyl-L-
alanine amidase is an important mechanism for inactivation of inflammatory 
peptidoglycan products. 
INTRODUCTION 
The presence of N-acetylmuramyl-L-alanine amidase (NAMLAA) in 
human senun was first described by Ladesi6 et al. [25] who showed that the 
enzyme degrades peptidoglycan, a main component of bacterial cell walls, by 
hydrolyzing the lactyl bond connecting the glycan strands with the peptide side 
chain (see Fig. I). Later, the presence of NAMLAA in human serum was 
reported by only 3 other groups [39,38,32]. We recently purified NAMLAA 
from human plasma and found it to be present in human granulocytes but not 
in monocytes [15]. The biological function of this enzyme was never investi-
gated but might be important because of the potent biological and immunolo-
gical effects of peptidoglycan in vivo, including sleep induction [17,18,29], 
complement activation [42], adjuvant activity [19], activation of macrophages 
[10] and T cell mediated atthritis induction [36,35,34,24]. 
When undergoing an infection our body is exposed to bacterial cell wall 
products including peptidoglycan. However, also under normal conditions 
peptidoglycan can be found in human tissues. In a previous study we were able 
to isolate macromolecular peptidoglycan from human spleen [14]. The results 
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Figure 1. SimlJlified representation of the different peplidoglycan subunits. Alternating N-acet)'1 muramic acid 
(MurNAc) and N-acety! glucosamine (G1cNAc) form long sugar chains interlinked by peptides, resulting in a large high 
molecular weight network. N-acetylmuramyl-L-alanine amidase (NAMLAA) hydrolyses the lactate bond between 
MurNAc and the first amino acid of the peptidoglycan chain L·AJanine (-», Lysozyme hydrolyses the bond between 
MurNAc and GlucNAc (-~). 1= inlerpeptide bridge which may vary between microorganisms. 
were confirmed by immunohistochemical studies, which also showed the 
presence of peptidoglycan in other tissues [31]. Lehtonen et a!. [28] found 
muramic acid, a characteristic aminosugar of peptidoglycan, in human periphe-
ral blood leukocytes. These results suggest that our body tissues are continuous-
ly exposed to these bacterial products. It is therefore important to investigate 
how these products are eliminated and loose their inflammatory properties. 
In humans, peptidoglycan can be degraded by 3 different enzymes: 
lysozyme [20], J3-N-acetylglucosaminidase [37,41] and the relatively unknown 
NAMLAA. We hypothesize that NAMLAA plays an important role in the 
degradation and inactivation of inflammatOlY peptidoglycan present in human 
tissues. To investigate this hypothesis we analyzed the effect of peptidoglycan 
degradation by NAMLAA in different in vivo and in vitro assays. 
The source of peptidoglycan was a preparation of cell wall fragments 
from EubacteriulII aerojaciens (ECWF) a major resident of the human intestinal 
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flora. In previous studies with Lewis rats we showed that ECWF induced 
severe chronic joint inflammation after a single intraperitoneal injection in PBS 
but also as an emulsion in oil (incomplete Freund adjuvant) [24]. The latter 
model was used in the present study to test the arthritogenicity of ECWF after 
solubilization with lysozyme and subsequent incubation with NAMLAA. The 
same preparations were also used for induction of TNF-a, IL-J and IL-6 in 
vivo and in vitro. The inflammatOlY cytokines [2] were used as a measure for 
activity of peptidoglycan digests. The results show the effect of NAMLAA on 
the cytokine and atihritis inducing capacity of ECWF. 
MATERIALS AND METHODS 
Peptidoglycan degrading enzymes 
N-acetyll11uramyl-L-alanine amidase (46 U/mg) was purified from human plasma using an 
affinity chromatography column prepared with a monoclonal antibody against the enzyme, as was 
previously described [15]. In short: Monoclonal antibody AAA4 raised against NAMLAA, was 
coupled to CNBr-activated Sepharose 4B beads (Phannacia LKB Biotechnology, Uppsala, 
Sweden) according to the protocol of the supplier. Human plasma (obtained from Red Cross 
Blood Center, Rotterdam) was dialyzed against PBS and diluted 2 times in PBS before it was 
loaded onto the column, The column was washed with PBS until no more protein was detected in 
the eluate. NAMLAA was eluted from the column by changing the buffer to 0.1 M Glycine'HCI, 
pH 3.0. The peak fractions were immediately dialyzed against 20 mM NH4HC03 pH 8.0. Egg 
white lysozyme was obtained from Sigma, St Louis, MO) 
Preparation of cell wall fragments (ECWF) 
Eubacterium ael'ofaciens ATeC 25986 was obtained from the American Type Culture 
Collection (Rockville, MD) and was cultured overnight at 37'C on Schaedler broth (Oxoid Ltd., 
London, UK) under strict anaerobic conditions. ECWF were prepared according to Severijnen et 
al. [36] with slight modifications. Cells were harvested, washed and subsequently fragmented 
with glass beads in a Braun shaker (Melsungen, FRO). Cell walls were collected by 10,000 xg 
centrifugation, treated with ribonuclease and trypsin, washed and sonicated (MSE, Crawley, UK) 
for 75 minutes. The sonicated cell wall suspension was centrifuged 30 minutes at 1000 xg. The 
supernatant was centrifuged at 100,000 xg for 60 minutes. The pellet was collected, resuspended, 
dialyzed against water (milli-Q, MiUpore) and subsequently lyophilized. All ECWF preparations 
were tested for endotoxin contamination by the Limulus Amoebocyte Lysate test at a sensitivity 
of 2 pglml. Even in the highest concentration used, the endotoxin concentration was lower than 2 
pglml. Teichoic acid concentrations were measured by detecting phosphorus using the method of 
Chen et al. [4]. The cell waU preparation contained 0.5% phosphor (dry weight) corresponding 
with about 2 to 3% teichoic acids, 
Lysozyme and NAMLAA digestion of ECWF 
For the arthritis induction in rats and cytokine induction in mice the solubilized fraction 
of ECWF after lysozyme treatment was used. 10 mg ECWF and I mg lysozyme in 10 mM 
sodium acetate was incubated during 24 h at 37°C and centrifuged at 100,000 xg. The supema-
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tant was dialyzed against milli-Q water and lyophilized. This preparation is further referred to as 
ECWF+Lso1. For in vitro cytokine induction 10 rug ECWF was incubated with I rug lysozyme in 
5 mM sodium acetate for 24 h at 37°C. Without further centrifugation and dialysis this preparati-
on is further referred to as ECWF+L. 
NAMLAA digestion of ECWF was carried out by incubating 5 mg/ml ECWF+Lsol or 
ECWF+L with 25 ~g/ml NAMLAA in 20 mM NH4HC03 for 24 h at 37'C. These preparations 
are further referred to as ECWF+Lso1+A and ECWF+L+A. 
Determination of N-acetyl muramic acid (MurNAc) 
MurNAc was detemlined according to the method of Hadzija [11] with somc modificati-
ons [12]. In short: samples were hydrolyzed by heating for 3 h at 90°C with an equal volume of 
5 M H2S04, then neutralized with 10 M NaOH. Hydrolyzed and unhydrolyzed samples (100 ~I) 
were incubated with 50 ~I I M NaOH at 36°C for 30 min. After the addition of I ml 18.8 M 
H2S04 (concentrated), samples were heated for 3.5 min at 100°C, rapidly cooled in ice, then 
mixed with 10 III 0.16 M CuS04.5H20 in H20 and 20 ~I 0.09 Mp-hydroxydiphenyl in ethanol. 
The blue color developed to a maximum in 30 min at 30°C. Absorbance at 570 nrn was 
determined using a Titertek Multiskan (Flow Laboratories, Irvine, Scotland). Solutions containing 
0-100 J..lg MurNAc (Sigma) per ml H20 were used as standards. The data are given as the 
concentration in the hydrolyzed and non-hydrolyzed samples. Subtraction of the values represent 
the amount of MurNAc linked to the peptides (net). MurNAc values were corrected for the 
presence of pentoses (rhamnose) using the method of Disehe and SheNles [6]. In ECWF 
rhamnose is responsible for approximately 20% of the measured MurNAc concentration. 
Animals and induction of arthritis 
Female Lewis rats (Harlan Sprague Dawley, Bicester, Oxfordshirc, UK) 7-8 weeks of age 
were injected subcutaneously in the base of the tail with J mg lyophilized ECWF digested with 
lysozyme, NAMLAA or both, adequately ground in 100 J..lI of Freund's incomplete adjuvant 
(Difco Laboratories, Detroit, MI) using a homogenizer (X 10/20, Ystral, ballrechten-Dottingen, 
FRG). Freund's incomplete adjuvant was used as a negative control. Rats were observed and paw 
diameters were measured for at least 100 days, twice a week. When the paw diameters increased 
compared to the diameters measured before the treatment and compared to the negative controle 
rats, the animal was counted positive. The arthritis was confinned by histology as was described 
by Kool et al. [24]. 
Induction of cytokine release in BALB/c mice 
ECWF aner lysozyme solubilization (ECWF+Lso1) and lysozyme + NAMLAA 
(ECWF+Lsoi+A) solubilization were diluted in sterile PBS to a final concentration of 0.2 mg/mt. 
0.5 ml was injected in a vein of the tail. There were 4 groups: mice injected with ECWF+Lso1, 
ECWF+Lso1+A, LPS (0.2 ~g/ml) and PBS. One hour and two hours after injection, 3 mice per 
group were killed by CO2, the blood was recovered by heart puncture and collected in a tube 
containing sodium citrate. The blood samples were immediately put on ice and after centrifugati-
on at 4°C the plasma was used for detection of cytokines. 
Induction of cytokine I'cleasc by human peripheral blood monocytes 
Human peripheral blood mononuclear cells were isolated by the method of Boyum from 
blood freshly obtained from healthy donors [3]. The blood was collected in sodium-citrate 
containing tubes (Vacuette, Greiner, Kremsmuenster, Ostria). After I: 1 dilution in sterile PBS the 
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cells were separated by ficoll density centrifugation, 15 minutes, 1000 xg (Fico II paque, 1.077 
glml, Phannacia). The interphase was diluted in PBS and centrifuged for 5 min. 400 xg. The 
pellet was then resuspended in Medium J 99 containing glutamax (GmeO, Breda, the Nether~ 
lands). Cells were counted and medium was added until a final concentration of 3 x 106 cells/ml. 
The cells were transferred to flat-bottom tissue culture plates with 96 wells (Falcon, 
Lincoln Park, NY), 100 ~t1 per well and then incubated for I hour at 37°C in a 5% CO2 atmosp-
here in order to let the cells adhere. Non adherent cells were aspirated and 100 1-11 ECWF 
preparations or LPS (E. coli 026:B6, Difea Laboratories) dilutions were added to the remaining 
monocytes in triplicate. All ECWF dilutions were made in Medium t 99 containing J 0 J.tg/ml 
polymyxin 8 (Sigma), As a control the monocytes were incubated with medium alone. At 
maximum stimulation after 6 hours the supernatants were frozen to bc tested later in bioassays 
for IL-l, IL-6 and TNF-a. 
Induction of cytokine release in whole blood 
Human peripheral blood was obtained from healthy donors and collected in sodium-
heparin tubes (Vacutainer, Becton Dickinson). 12.5 III of Medium 199 containing 100 ~glml 
polymyxin 8 and the different ECWF preparations or LPS dilutions were transferred to a 
polypropylene tube (Falcon) containing 122,5 ~" blood, The mixtures were incubated for 5 hours 
at 37°C in a 5% CO2 atmosphere. Then 125 ~I RPMI (1640 GIBCO) was added to each tube 
and the mixtures were centrifuged for 10 min, 400 xg. The obtained supernatants were tested in 
bioassays for IL-I, IL-6 and TNF-a activity. 
Bioassays for cytokines 
TNF-a bioactivity was measured using the murine fibroblast cell line WEHI J 64. J 3 [8]. 
The cells were plated in flat-bottom tissue culture plates with 96 wells (Costar, Cambridge, MA) 
at a concentration of 1 x lOS cells/well. The cells were allowed to adhere by incubating them 
ovemight at 37'C in a 5% CO2 atmosphere. At day two 50 ~I of Actinomycine-D (Sigma) 4 
J.lglml and 50 J..II diluted sample were added to the cells, Samplcs were tested in triplicate. After 
an overnight incubation (37°C, 5% CO2) the MIT cytotoxicity test [33] was used to measure 
WEHI cell viability. 
IL-J bioactivity was measured using a sub line of the murine T cell line DIO,G4.l, 
designated DI0(N4)M using the method described by Hopkins and Humphreys [16] with some 
modifications [5]. 
IL-6 activity was detected by using the murine hybridoma cell line 89 according to 
Aarden et al. [I]. Proliferation of D 1O(N4)M and B9 cells was measured by 3H-thymidine 
incorporation. Recombinant human IL-IB (UBI, Lake placid, NY), IL-6 (Prof. Dr. L.A. Aarden, 
CLB, Amstedam, The Netherlands) and TNF-a (UBI) served as positive controls for the DIO, B9 
end 'VEHI assays, Cytokine activities of the samples were corrected for background activity of 
the culture medium and expressed as U/ml with I U/ml corresponding with half-maximal 
response. 
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RESULTS 
N-acetylmuramic acid (MurNAc) in ECWF preparations after incubation 
with lysozyme and NAMLAA 
After incubation of ECWF with lysozyme and NAMLAA the concentrati-
on of MurNAc was determined with and without hydrolysis (see M&M). The 
results are presented in Table I. The difference found with and without 
hydrolysis corresponds to the amount of peptides still connected to muramic 
acid via the D-Iactate group (see Fig. I). The data show that incubation of 
ECWF with lysozyme did not change the concentration of MurNAc linked to 
the peptides in the ECWF+L nor in the centrifuged and subsequently dialyzed 
ECWF+L sol preparations. 
Fmiher treatment with NAMLAA resu Ited in an increase of MurNAc 
found without hydrolysis due to the liberation of peptide from the D-Iactate 
group of MurNAc. The amount of intact peptidoglycan was therefore reduced 
(expressed as net). 
Table 1. N-acetyl muramic acid (MurNAc) in Eubactel'ium aerofaciens cell wall fragment 
(ECWF) preparations incubated with lysozyme (L) and NAMLAA (A) with and without 
hydrolysis 
• pg MurNAc 
.. 
hYdrolysis no hydrolysis net 
ECWF 130 22 108 
ECWF+Lsol 155 45 110 
ECWF+Lso1+A 157 106 51 
ECWF+L 169 32 137 
ECWF+L+A 168 112 56 
• Expressed as ~Ig MurNAc per mg dryweight. Corrected for the presence of pentoses . 
.. Net value is a measure of the amount of peptides still linked to MurNAc sol: supernatant after centrifugation. 
Influence of lysozyme and NAMLAA digestion on artitritogenicity of 
ECWF 
Severe chronic polyarthritis was induced in Lewis rats by subcutaneous 
injections of ECWF in oil. 32 out of 56 rats developed arthritis. The onset was 
3 to 6 weeks post injection and the arthritis lasted for the entire observation 
period of 10 weeks. The arthritis was confirmed by histological examination of 
the affected joints. The lysozyme treated fraction of ECWF (ECWF+Lsol) was 
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also tested for at1hritogenicity. 15 out of 50 rats developed arthritis. The onset, 
chronicity and histological characteristics were similar to those observed for 
rats injected with ECWF. The incidence was significantly lower than with 
untreated ECWF (p<0.05). ECWF+L was further treated with purified NAM-
LAA resulting in a 50% decrease of peptides still linked to muramic acid. This 
preparation was not capable of inducing arthritis in 19 rats (p<O.O I). This 
means that there was no increase in paw diameter measurable. 
Table 2. The average cytokine production# in the blood of mice injected with lysozyme 
solubilized Eubacterium aero/acieJls cell ,,"'all fragments before (EC'VF+Lso1) and after 
(EC\VF+Lso1+A) amidase tI'catment, 1 hour and 2 hours after iv injection 
TNF-c< 
IL-I 
IL-6 
TNF-c< 
IL-I 
IL-6 
ECIVF+Lsol 
310 ± 321 
ND 
5.6 ± 1.2 
44.7 ± 12.1 
ND 
2.2 ± 0.8 
# V/ml ± SO; 3 mice per group. 
ECIVF+Lsol+A 
58.2 ± 15.5 
ND 
2.6 ± 2.1 
16.8 ± 11.0 
ND 
0.7 ± 0.3 
I hour 
p' 
0.29 
-
0.03** 
2 hours 
0.06" 
-
0.06" 
• The two-tailed p value determined with paired I-lest. 
•• Not significant according to two-tailed p value calculated with the paired wilcoxan signed nmk lest. 
ND = Not detectable « 0.02 U/ml). 
Induction of TNF-a, IL-t and IL-6 release in BALB/c mice 
LPS 
1490 ± 733 
15.1 ±6.4 
4.7 ± 0.2 
145 ± 125 
30.7 ± 8.1 
3.5 ± 0.3 
Table 2 shows the cytokines released in the blood of BALB/c mice upon 
injection of lysozyme and NAMLAA digested ECWF. After degradation of the 
lysozyme solubilized ECWF by purified NAMLAA (ECWF+Lso1+A), the 
capability of the preparation to induce TNF-a and IL-6 release was 2-3 times 
lower than after degradation by lysozyme alone. The decrease in TNF-a release 
I hr after injection was not statistically significant, so was the decrease measu-
red after 2 1m (p=0.062). The trend, however, was consistent and similar 
results were obtained with IL-6. The decrease in IL-6 release I hI' after 
injection was significant (p=0.033), but at 2 hours after injection the decrease 
was no longer significant (p=0.056). 
77 
Chapter 5 
1000 
TNF-a 
800 
~ 
~ 
~ 800 
... 
~ 
~ 400 
~ 
~ 
200 
0 
[CWFtL EC\\TIL+A 
70 
fL-! 
" 
~ 
~ 
42 ~ 
... 
~ 
-d 
" ~ 
" 
0 
ECWI'+L ECV'l'tL+A 
25 
IL·6 
20 
~ 
~ 
~ 
... 16 ~ 
~ 
:l 
~ 10 
~ 
~ 
o 
"""" """" 
t222J 
$ ~!fml 2.S ,tJnt 0_1 Hf.d 
Figure 2. Induction of 1NF-o:. IL·l and IL-6 ex vivo, after stimulation of whole blood with lysozyme treated and 
lysozyme plus NAMLAA treated (ECWF+L and ECWF+L+A) EubacteriulII aerojacielLl' cell wall fragments in four 
different concentrations based on muramic acid contents. Values represent the mean of 10 independent experiments using 
10 diO'erent blood donors (± SD). 
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Table 3. The average cytokine concentration# after stimulation of PBMC with 2.5 J,tg 
lysozyme treated Eubacterium aerofaciells cell wall fragments before (EC\VF+L) and after 
(ECWF+L+A) NAMLAA treatment 
ECWF+L ECWF+L+A p' 
TNF-a 6.3 ± 2.3 3.4 ± 1.7 0.06 
IL-I 24.0 ± 48.6 9.1 ± 12.1 0.35 
IL-6 729 ± 592 455 ± 520 0.12 
# Vlml ± SD; 10 samples per group . 
• The two-tailed p value determined with paired t-test. 
The effect of NAMLAA treatment on the IL-I levels was not clear. In 
the ECWF+L and ECWF+L+A stimulated mice, biologically active IL-I was 
undetectable «0.02 U/ml). However, the negative control and in the LPS 
stimulated samples contained detectable IL-J levels. The results indicate that 
the peptidoglycan constituent of the cell wall fragments, the only moiety that is 
affected by NAMLAA, is responsible for the cytokine release. It further 
supports the hypothesis that NAMLAA degradation is an important mechanism 
for inactivating the inflammatory properties of peptidoglycan products. 
Induction of TNF-a, IL-l and IL-6 release in vitro using whole blood or 
peripheral blood mononuclear cells 
After the hydrolysis of lysozyme treated ECWF by NAMLAA the 
capability of the product to induce cytokine production in whole blood was 
reduced. The values shown in Fig. 2 are the mean of 10 independent experi-
ments using 10 different human blood samples from various healthy donors. 
Table 3 shows the results after stimulating with 5 Ilgfml ECWF+L and 
ECWF+L+A. The two-tailed p values, calculated with the paired t-test, were 
significant for all cytokines (p<O.OI) 
After stimulation of the adherent peripheral blood monocytes, the values 
between 10 independent experiments differred a lot from each other due to the 
high variety between the donors. Therefore only one representative experiment 
is shown in Fig. 3. In table 4 the average cytokine production is given of 
PBMC stimulated with 2.5 Ilgfml ECWF+L and ECWF+L+A. The differences 
in TNF -ct, IL-I and IL-6 production were not significant, although the trend 
was consistent in all experiments. In both assay systems all the blood samples 
from the 10 different healthy donors showed a reduced cytokine release when 
the ECWF preparation was hydrolysed by NAMLAA. 
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Figure 3. Induction oflNF.(;(, IL·I and IL·6 release after stimulation of peripheral blood monocyles. The same stimuli 
were used as in Fig. 2. One representative experiment is shown from a total of to experiments. 
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Table 4. The average cytokine concentration# after stimulation of whole blood with 5 pg 
lysozyme treated EubacteriulII aerofaclells cell wall fragments before (EC\VF+L) and after 
(ECWF+L+A) NAMLAA treatment 
TNF-u 
IL-I 
IL-6 
/I Ulml ± SD; 10 samples per group. 
DISCUSSION 
ECWF+L 
330 ± 228 
36.4 ± 20.8 
20.5 ± 7.3 
ECWF+L+A • P 
150 ± 121 0.0019 
19.8 ± 12.8 0.0077 
15.4 ± 5.4 0.0012 
To our knowledge these are the first results on the biological activity of 
NAMLAA showing that degradation of peptidoglycan by this enzyme is an 
impOltant mechanism for inactivation of inflammatory peptidoglycan products. 
NAMLAA purified from human serum hydrolysed 50% of the lactyl-
peptide bonds from the peptidoglycan in ECWF after this had been incubated 
with lysozyme. Preincubation with lysozyme was necessaty because NAMLAA 
was not able to use the non-soluble ECWF as a substrate (unpublished results). 
Previous studies showed that ECWF was arthropathic in Lewis rats using either 
the intraperitoneal route [36] or ground in oil and injected in the base of the 
tail [23]. However, Fox et al. [9] showed that the soluble. fraction (after 
100,000 xg centrifugation) of streptococcal cell wall fragments did not induce 
arthritis in rats after intraperitoneal injection. Therefore the adjuvant route was 
used in this study. 
ECWF did not loose its arthropathic propelties after solubilization by 
lysozyme although the incidence was lower. Additional NAMLAA degradation 
did abolish the arthritis inducing capacity of this preparation. Whether this is 
due to the decreased molecular weight or to the destruction of specific inflam-
matory epitopes like the muramyl-peptide moiety, needs to be further investiga-
ted. Studies of Kohashi et al. [21,22] showed that even very small subunits of 
peptidoglycan were able to induce arthritis in the adjuvant model provided that 
they contained intact muramyl-peptide subunits. This might indicate that it is a 
prerequisite for arthritis induction that the peptide is linked to the MurNAc-
GlucNAc sugar chain. 
The cooperative action of lysozyme and NAMLAA is important to 
completely abolish the arthitogenic capacity of the cell wall fragments in the 
arthritis model used. This is consistent with the finding that ECWF can only be 
81 
Chapter 5 
degraded by NAMLAA after it has been solubilized by lysozyme. 
Intravenous injection of the solubilized fraction of ECWF in BALB/c 
mice resulted in an immediate cytokine release. LPS was a much more potent 
stimulator than the cell wall preparations. After ECWF stimulation no IL-I was 
detectable although after stimulation with LPS a high IL-I response was 
detected comparable to the responses described by Zanetti et al. [43). They 
found that injection of living Gram-negative bacteria resulted in high levels of 
IL-l. We do not know why no biologically active IL-I could be detected after 
stimulation with ECWF+Lsol. It might be due to the production of IL-I soluble 
receptors and/or IL-I receptor antagonist, interfering with the bioassay. This 
effect was not found when the whole blood assay was used. 
Stimulation of PBMC or whole blood with lysozyme treated cell wall 
fragments from E. ael'ojaciens (ECWF +L) resulted in the induction of TNF-a, 
IL-I and IL-6 comparable with the results described by Mattsson et al. [30], 
who stimulated peripheral blood monocytes with peptidoglycan from Staphy-
lococclls epidel'lIIidis, and Heumann et al. [13] who used 10 different Gram-
positive cell wall preparations for stimulation of TNF-a production by human 
monocytes. The concentrations of peptidoglycan used in the in vivo and in 
vitro studies were physiological since Lehtonen et al. [27] found in synovial 
fluids of patients with reactive atihritis 0.2 - 2 Jlg muramic acid per ml 
synovial fluid, corresponding with 1 -10 Jlg peptidoglycan per ml. This is in 
the same range as the MurNAc content of the preparations used for the 
experiments described in this paper. 
NAMLAA acts specifically on peptidoglycan. Therefore the reduction in 
cytokine induction after degradation by NAMLAA demonstrates that the 
peptidoglycan in the preparations used is primarily responsible for the cytokine 
release and arthritis induction. The remaining activity of the NAMLAA 
degraded cell wall preparations may be explained by the fact that they still 
contain low concentrations of teichoic acids which are able to induce cytokine 
release [30] and/or because they contain undigested peptidoglycan, caused by 
modifications which make peptidoglycan partly undegradable by lysozyme [26] 
and NAMLAA [15,40]. 
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Localization of human NAMLAA 
SUMMARY 
N -acetyl muramyl-L-alanine amidase (N AMLAA) specifically hydro Iyzes the 
lactamide bond that links N-acetylmuramic acid, in the polysaccharide chain of 
peptidoglycan, with L-alanine of the peptide side chain. Peptidoglycan is a bacte-
rial cell wall product with strong inflammatory properties. For instance, 
peptidoglycan is capable of stimulating peripheral blood cells to release pro-
inflammatory cytokines and is capable of inducing chronic arthritis in an animal 
model. In a previous study we found that degradation of peptidoglycan by purified 
NAMLAA reduced its inflammatory effects. To determine where NAMLAA is 
located in tissues, monoclonal antibodies against purified NAMLAA were 
produced for use in immunohistochemistry, immunoelectron microscopy, flow 
cytometric analysis and Western blotting. 
The immunohistochemical studies revealed NAMLAA-positive cells in 
human spleen, liver, arthritic synovial tissues and in lymph nodes. In flow 
cytometric studies of blood and bone marrow, neutrophilic and eosinophilic 
granulocytes proved to be positive. Monocytes were negative although they do 
contain lysozyme, the other impOitant peptidoglycan-degrading enzyme. However, 
mature macrophages obtained by bronchoalveolar lavage and subsequent selection 
based on auto-fluorescence did possess NAMLAA. In immunocytochemical 
staining of blood smears, thrombocytes were also positive for NAMLAA. Western 
blot analysis and immunoelectron microscopy of neutrophils and eosinophils 
showed that NAMLAA is located in azurophilic granules of neutrophils and in 
secretion vesicles and Clystalloid-containing granules of eosinophils. 
Flow cytometric analysis of blood and bone marrow from different F AB-
classified acute myeloid leukemia (AML) patients showed that AML-M2 
myeloblasts were the first in the granulocyte maturation lineage that were positive 
for NAMLAA. The more immature AML such as AML-MO and AML-MI, did 
not express NAMLAA. CD 15 and CD l3-negative megakatyoblasts, corresponding 
to AML-M7, were also positive for NAMLAA. 
INTRODUCTION 
In human sera N-acetylmuramyl-L-alanine amidase (NAMLAA) activity was 
reported for the first time by Laddie et al. [I). This relatively unknown human 
enzyme degrades peptidoglycan, a major component of most bacterial cell walls, 
by hydrolysis of the lactyl bond that connects N-acetylmuramic acid in the glycan 
strands with L-alanine of the peptide side chain (2). In a previous study we 
89 
Chapter 6 
described the purification of NAMLAA from human plasma, the preparation of 
monoclonal antibodies against it and the propelties of this enzyme [3]. 
Peptidoglycan is present in the cell walls of almost all bacteria and is the 
major constituent of the cell walls of Gram-positive bacteria. The inflammatOlY 
properties of peptidoglycan in vivo include complement activation [4], mthritis 
induction [5], and activation of monocytes and macrophages resulting in the 
release of inflammatOlY cytokind [6,7]. 
Following the lysis of bacteria during an infection, cell wall fragments 
containing peptidoglycan are rapidly cleared through the action of phagocytic cells 
and their hydrolytic enzymes [8]. Lysozyme is thought to be the most important 
enzyme for the inactivation of peptidoglycan, degrades the sugar backbone of 
peptidoglycan by hydrolysing the bond between N-acetylglucosamine and N-
acetylmuramic acid. However, in previous studies we and others showed that cell 
wall fragments from Gram-positive bacteria still possessed most of their 
inflammatory properties after degradation by hen egg-white lysozyme [9, lO], but 
lost most of their cytokine and arthritis-inducing capacity after degradation by 
NAMLAA [II]. This indicates that the presence of lysozyme alone is not 
sufficient for complete inactivation of the inflammatory properties of peptidogly-
can. 
The presence of a peptidoglycan-degrading enzyme other than lysozyme in 
phagocytic cells is therefore required for the complete processing of peptidoglycan. 
Apart from lysozyme, N-acetylglucosaminidase was repOlted to be present in 
granulocytes and was shown to hydrolyze the N-acetylglucosamine group from the 
non-reducing end of the glycan chains [12], although its primary function is the 
degradation of oligosaccharides containing B-glucosaminide linkages, present on 
many glycoproteins [13]. Whether the degradation by N-acetylglucosaminidase 
could have an effect on the inflammatOlY properties of peptidoglycan has not been 
investigated yet. It is, however, reasonable to assume that this enzyme has very 
little effect on these properties because of its limited enzymatic activity. Therefore 
the presence of NAMLAA in phagocytic cells might well complement the 
hydrolytic actions of lysozyme. 
In the present study, monoclonal antibodies raised against human NAMLAA 
were used for immunohistochemistry, electron microscopy, flow cytometric 
analysis and Western blotting to determine the localization ofNAMLAA in human 
tissues. Blood and bone marrow cells from healthy donors and from acute myeloid 
leukemic patients were analyzed to determine in which stages of myeloid 
differentiation NAMLAA is expressed. Bronchoalveolar lavage samples were used 
as a source of mature macrophages. 
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MATERIALS AND METHODS 
Preparation of monoclonal antibody AAA4 against NAMLAA 
Purified NAMLAA was used for preparing mouse monoclonal antibodies as described 
previously [3]. The IgO I monoclonal antibody AAA4 showed the highest affinity for NAMLAA and 
was used for conjugation with FITC (AAA4-FITC) by standard procedures [14]. In a previous study, 
AAA4 proved to be highly specific for NAMLAA and was used for the purification of NAMLAA 
in one step from human plasma [3]. 
Bronchoalveolar lavage 
Bronchoalveolar lavage samples, generously suppHed by the Department of Pulmonary 
medicine, University Hospital Rotterdam, the Netherlands, were obtained as follows. After informed 
consent, bronchoalveolar lavage was performed on individuals during anesthesia for surgery. The 
lavage was performed with a flexible bronchoscope placed in wedge position in the right middle 
lobe. Four aliquots of 50 ml of saline were subsequently instilled and aspirated. The obtained fluid 
was collected in siliconized bottles. 
The cells in the lavage fluid were kept at 4°C, washed twice in phosphate-buffered saline 
(PBS) containing 0.5% (w/v) bovine serum albumin (BSA) and 0.45% (w/v) glucose. The celis were 
then filtered through a 100-~m and a 30-~m gauze and subsequently sorted on a FACS-Vantage 
(Becton Dickinson, Erembodegem, Belgium) with a laser operating at 488 nm. The highly 
auto fluorescent (530 nm) population was used to prepare cytospins and was shown to contain 100% 
alveolar macrophages. The cells were stained with AAA4 as described under immunocytochemistry 
(see below). 
Immunocytochemistry 
For the preparation of smears, blood and small bone marrow samples were obtained after 
informed consent from a healthy donor by the Department of Hematology, Erasmus University 
Rotterdam. The smears were fixed and penneabilized by incubation for 10 minutes in acetone. The 
smears were then rinsed in PBS containing 0.2% BSA and incubated for I hour at room temperature 
with 70 ~I of AAA4 (diluted 40 ~'g!ml in PBS-BSA) or, for control staining, with an irrelevant 
monoclonal antibody of the same isotype and concentration. Subsequently, the smears were rinsed 
in PBS-BSA and incubated for 30 minutes at room temperature with rabbit-anti-mollse immunoglo-
bulin (Z259; DAKO, Olostrup, Denmark) diluted 1:20 in PBS-BSA with 1% nonnal human serum. 
After rinsing in PBS-BSA, a J :40 dilution of alkaline phosphatase-mouse-anti~alkaline phosphatase 
complex (APAAP, D65 J; DAKO) was applied for 30 minutes. To develop the stain, the smears were 
incubated for 30 minutes at room temperature with 0.012% (w/v) naphthol-ASMX phosphate, 
0.025% (w/v) fast blue BB base and 0.025% (w/v) levamisol (ali from Sigma, SI. Louis, MO), which 
stains positive cells blue. Granulocytes were easily identified by the negatively-stained nucleus, 
rendering a counter stain unnecessary. Finally, the smears were mounted in Kaiser's glycerol gelatin 
(Merck, Dannstadt, FRO). 
Immunohistochemistry 
For the immunohistochemical studies, spleen tissue was obtained from the Department of 
Pathology immediately after surgery (SSDZ, Delft, The Netherlands). The spleen was removed for 
technical reasons from a patient with gastric adenocarcinoma. Liver biopsies obtained from the 
Department ofPatho!ogy, Erasmus University Rotterdam, were taken from an organ being prepared 
for transplantation. Lymph nodes were obtained from a patient undergoing surgery for tonsillitis. 
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Synovial tissues were obtained at the time of reconstructive surgery from the knees and hips of 
patients with definite or classical rheumatoid arthritis according to the American Rheumatism 
Association criteria. 
For immunohistochemical staining with the monoclonal antibody AAA4, tissue cryostat 
sections were acetone-fixed as described previously [15]. Only the spleen cryostat sections were fixed 
with pararosaniline. The staining procedure was the same as described above for immuno-
cytochemistry. 
Immunohistochemical double staining 
For double staining with two monoclonal antibodies, the tissue cryostat sections were fixed 
as described above. Endogenous peroxidase activity was blocked by a lO-min incubation in 0.5% 
H20 2 in PBS. The sections were washed in PBSIBSA and subsequently incubated with monoclonal 
AAA4 for J h at room temperature. As the second step. APAAP was used as described above. After 
incubation and washing in PBSIBSA. the sections were incubated with the second monoclonal 
antibody for I h at room temperature. The antibodies used are listed in table 1. The staining was 
detected with a peroxidase-conjugated rabbit anti-mouse-immunoglobulin (P i61. DAKO) in a J :250 
dilution in PBSIBSA with 1% nomlal human serum. After a 3D-min incubation and washing in 
PBS/BSA. the sections were incubated with the alkaline phosphatase substrate for 45 min in the dark, 
Table 1. Immunohistochemical double labeling with AAA4 on human spleen 
Code Specificity 
RV202 Vimentin 
585 Fibroblasts 
HLE-I CD45, Leukocytes 
HLA-DR MHC-ll 
Leu4 CD3, T cells 
B4 CDI9, B cells 
Mac Macrophages 
L25 Dendritic cells 
LeuM3 CDI4, Monocytes 
CD24 Granulocytes 
VIM-D5 CDl5, Neutrophilic 
granulocytes 
Concentration double labeling 
used 
1:10 
1:20 
1:100 + 
1:250 
1:100 
1:100 
1:500 
1:500 
1:100 
1:100 + 
1:100 + 
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followed by rinsing in PBSIBSA and 0.2 M sodium acetate buffer, pH 4.6. The 
peroxidase substrate 3-amino-9-ethylcarbazole was applied for 30 min. Finally, the 
sections were rinsed in PBSIBSA and distilled water and mounted in Kaiser's 
glycerol gelatin. 
Flow cytometric analysis 
Blood and bone marrow was sampled for diagnostic purposes from AML 
patients and were FAB classified [16,17]. As a control, peripheral blood and bone 
marrow, obtained for diagnostic purposes, from a healthy donor were used. The 
cells were stained for intracellular antigens according to SYljala [18]. In short, 100 
fll of heparinized blood was incubated with the relevant conjugated antibodies for 
10 minutes at room temperature. The antibodies used for flow cytometric analysis 
were: CD3-PerCP, CD4-FITC, CD8-PE (Becton Dickinson Immunocytometry 
systems, San Jose, CAl, CDIO-PE, CDl4-PE (Coulter, San Fransisco, CAl, CDl5-
PE (Immuno Quality Products, Groningen, The Netherlands) and CDI9-TC 
(Sanbio, Uden, The Netherlands). The cells were then lysed and fixed by adding 
2 ml of FACS Lysing Solution (Becton Dickinson) and incubating for 10 min at 
room temperature. The cells were centrifilged and washed twice with PBS + 0.5% 
BSA and incubated with AAA4-FITC for 10 min. Again the cells were washed 
twice with PBS-BSA and were finally resuspended in 200 fll of FACS Flow 
(Becton Dickinson). The analyses were performed with a FACScan flow cytometer 
(Becton Dickinson, Sunnyvale, CAl. 
Cryo ultramicrotomy and immunolabeling 
Leukocytes from peripheral blood were fixed with a mixture of 0.5% (v/v) 
glutaraldehyde and 4% (w/v) paraformaldehyde in 0.1 M phosphate buffer (pH 
7.2) for I hour and were pelleted in 10% (w/v) gelatin in PBS. Ultrathin frozen 
sections were incubated at room temperature with AAA4 (60 flg/ml), followed by 
incubation with rabbit-anti-mouse-IgG (1/40) and 10-nm gold-conjugated goat-
anti-rabbit-IgG (1140). In double-labeling experiments, the cryosections were 
incubated first with AAA4, followed by incubation with rabbit-ant i-mouse IgG and 
5-nm gold-conjugated goat-anti-rabbit-IgG and then with 1% glutaraldehyde for 
10 minutes. Subsequently, the sections were incubated with rabbit-ant i-human 
myeloperoxidase (MPO, 111500) or rabbit anti-human lactoferrin (LF, 11200) and 
anti-rabbit-IgG linked to IO-nm gold (MPO and LF were from Cappel Laborato-
ries, Cocharanville, PA; anti-rabbit gold conjugates were from Amersham 
Nederland, 's-Hertogenbosch, The Netherlands). As a control, the primary 
antibody was replaced by a non-relevant murine or rabbit antibody. After immuno-
labeling, the cryosections were embedded in a mixture of methylcellulose and 
uranyl acetate and examined with a Philips CMIO electron microscope (Eindho-
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Figure 1. Immunocytochemistry of blood and bone marrow. 
A). Blood smear from a healthy donor stained ,\lith MoAb AAA4, shows NAMLAA-posilive granulocytes and a NAMLAA-
negative monocyte. B). Bone marrow smear after staining with AAA4 shows a NAMLAA-positive promyelocyte and a mature 
granulocyte. 
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ven, The Netherlands). 
Preparation of neutrophil fractions and Western blot analysis 
Neutrophil fractions were isolated essentially as described by Bolscher et al. 
[19], except that a sucrose gradient of 15/40/52/60 % (w/v) was used to recover 
the plasma membrane, specific granule and azurophilic granule fractions. 
The granulocyte fractions were subjected to 10% SDS-PAGE. Samples of 
20 ~tl were boiled for 3 min with 5 ~tl of loading buffer (60 mM Tris' HCI pH 6.8; 
23% glycerol; 3% SDS; 0.06% bromophenol blue; 10% 2-mercaptoethanol). Ten 
III of these samples were analyzed on 10% SDS-PAGE (Mini Protein, BioRad, 
Richmond, CA). Samples were transferred to nitrocellulose in 25 mM Tris, 190 
mM glycine and 20% methanol transfer buffer. Aspecific binding sites were 
blocked by incubating the nitrocellulose sheets in low-fat milk for 30 minutes and 
subsequently washing three times with 0.5% Tween-20 in PBS. The nitrocellulose 
sheets were then incubated for 1 hour at room temperature with monoclonal 
antibodies diluted 500 times in PBS-Tween. Following three washes, goat-anti-
mouse-IgG conjugated to alkaline phosphatase (DAKO) was added in a 1000-times 
dilution, and the blots were incubated for I hour at room temperature. The blots 
were washed three times with PBS-Tween and then three times with PBS. For 
visualization of antibody-antigen complexes, the alkaline-phosphatase substrate 
nitroblue tetrazolium/5-bromo-4-chloro indoxyl phosphate (NBTIBCIP) was used 
as described [20]. 
. 
Figure 2. Bronchoal\'eolar macrophages, sorted for high auto·fluorescence, were stained for NAMLAA. Twenty percent 
of the macrophages stained positive. 
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Figure 3. Flow cylomelric analysis or bone marrow rrom a heallhy donor. 
Double labeling was performed with AAA4/CDI4 and AAA4ICDI5. The scatter morphology of the bone marrow sample and 
the control slainings with IgG·FITC and IgO·PE are given in respectively A) and B). Double-labeling of bone marrow cells 
with the NAMLAA·specific antibody AAA4-FITC and the monocyte marker CDI4-PE (C) or the granulocyte marker CDt5. 
PE (D) show that CDl4'positive monocytes (Box I in fig. C) are negative for the NAMLAA marker AAA4, whereas the 
CDl5'positive ceJls are positi\'e for AAA4 (D). Boxes 2 and 3 in fig. C represent mature and immature granulocytes, 
respectively. 
RESULTS 
Localization of NAMLAA in human tissues 
NAMLAA-positive cells were found in human spleen, liver, lymph nodes 
and synovial tissues of arthritis patients and healthy controls. Double staining of 
spleen tissue for NAMLAA and a variety of markers for fibroblasts, HLA class-II, 
T cells, B cells, monocytes, macrophages, dendritic cells and granulocytes (Table 
I) showed double staining of granulocytes only (data not shown). 
Immunocytochemical studies (Fig. 1) of blood and bone marrow showed 
that granulocytes, but not monocytes, stained positive for NAMLAA. Fig. IB 
shows that myeloblasts were negative, while band-form granulocytes were 
positively stained for NAMLAA. Although monocytes and spleen macrophages did 
not express NAMLAA, a 20% subpopulation of highly fluorescent bronchoalveolar 
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Figure 4. Flow cylomelric analysis of bone marrow from an AML-M3 classified patient. 
The mononuclear cells contain more than 80% NAMLAA (AAA4-FITC)-posilive and eDlS·negative promyelocytes. 
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Figure 5, Hypothetical scheme of myeloid differentialion. 
The expression of NAMLAA is indicated for each differentiation stage with + and -, The bars represent the various types 
of leukemias and non-Hodgkin lymphomas and indicate where these malignancies can be located according to their maturation 
arrest. To indicate the heterogeneous phenotype found in most AML patients. the bars fade into each other, CML=chronic 
myeloid leukemia, NHL=non·Hodgkin lymphoma. 
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macrophages was positive for NAMLAA (Fig. 2), indicating that differentiation 
of monocytes to macrophages induces NAMLAA expression. 
The observation that granulocytes stain positive, and that monocytes and 
lymphocytes were negative, was confirmed by flow cytometric analysis of 
peripheral blood and bone marrow from a healthy donor. Double-labeling of bone 
marrow cells for NAMLAA and CDl4 or CDIS showed that the CDl4-positive 
monocytes were NAMLAA-negative while the CD IS-positive cells, representing 
granulocytes, were NAMLAA-positive (Fig. 3). Immature granulocytes (CDIS 
low) showed a higher NAMLAA expression than the CD IS high, mature 
granulocytes (Fig. 3D). In double-labeling experiments, neither the B cell marker 
COlO or CDl9 nor the T cell marker CD3, CD4 or CD8 stained NAMLAA-
positive cells. This indicates that in blood and bone marrow NAMLAA expression 
is restricted to the myeloid lineage. 
Expression of NAMLAA in various AML 
Blood and bone marrow from FAB-classified AML patients were screened 
for NAMLAA-positive cells. MO (myeloid precursor), M I (myelo-monocytic 
precursor) and M4 (monoblast) leukemic cells were negative, whereas M3 
(promyelocyte) leukemic cells were positive (Fig. 4). Also CML (myelocyte) and 
M7 (megakaryoblast) cells were positive (Fig. 5). In the myeloblast stage (M2), 
leukemic cells from one patient were NAMLAA-positive, while those of two other 
patients were negative, suggesting that expression of NAMLAA statts at this stage 
of granulocyte maturation. 
Localization of NAMLAA in granulocytes 
Immunoelectron microscopic studies were performed on ultrathin clyosecti-
ons of neutrophils and eosinophils. The sections were incubated with the 
NAMLAA-specific monoclonal antibody AAA4 and were subsequently stained 
with gold-labeled antibodies. The gold label was found in vesicles and granules 
of neutrophils (Fig. 6a). No background staining was found on the nucleus. The 
granules were subsequently characterized in double-labeling experiments. Myeloid 
peroxidase, a marker of azurophilic granules, colocalized with NAMLAA in some 
but not all azurophilic granules (Fig. 6b). No co localization was found with 
Figure 6, Cryosecfions of neulrophils from peripheral blood. 
A) Localization ofNAMLAA after incubation with the NAl\.ILAA·spedfic MAb AAA4. The gold label is shown in vesicles 
and granules (arrows), No background is shown on the nucleus (n); B). Micrograph showing double labeling for NAMLAA 
(5 nm gold) and myeloperoxidase (MPO), a marker for azurophilic granules (to nm gold). Both labels were seen in some 
but not in all MPO-positive azurophilic granules. C) Localization of lacloferrin (10 nm gold) and NAMLAA (5 nm gold) 
showed that the lactoferrin· positive specific granules (s) were not labeled with AAA4, while other granules/vesicles were 
labeled with AAA4 (arrows). Bars, A) = 200 nm; B) = 50 nm; C) = 100 nm. 
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lactoferrin (Fig. 6c), a marker for specific granules. NAMLAA was more abundant 
in the crystalloid containing granules and vesicles of eosinophils (Fig. 7). In the 
vesicles it seemed membrane bound (Fig. 7b). Monocytes present in the same 
sections were negative for NAMLAA. 
To confirm the results obtained by immunoelectron microscopy the 
localization of NAMLAA in neutrophilic granulocytes was investigated also by 
Western blotting. The neutrophilic granulocytes were fractionated into a semi-
purified membrane fraction, a cytosolic fi'action without membranes, a fraction 
containing mainly specific granules and a fraction containing mainly azurophilic 
granules. The fractions were then analyzed by Western blot. As shown in Fig. 8, 
the membrane fraction (lane 5) and the azurophilic granule containing fraction 
-
• 
M 2 3 4 5 
Figure 8. Western blot o( neutrophil cell (raelions. 
Lane M corresponds to pre-stained mole('ular weight markers of 116. 80. 49 and 32 kDa. Lane I ('orresponds to purified 
NAMLAA from human plasma. lanes 2. 3, 4 and 5 correspond to the azurophilic granule-('ontaining fraction, the cytosol 
fraction, the specific granule-containing fraction and the purified plasma membrane fraction, respectively. Only the azurophilic 
granule-containing fraction and the membrane fraction were recognized by MoAb AAA4, producing a band with a lower 
molecular mass than the NAMLAA purified from plasma in lane I. 
Figure 7. Cryosections o( eosinophils (rom peripheral blood incubated wHh MoAb AAA4. 
A) area of an eosinophil showing labeling for NAMLAA on the crystalloid containing granules (arrows). B) Area of another 
eosinophil showing labeling on the same granules (thick arrows) and on the membrane of small vesicles (small arrows). Bar 
= 200 nm. 
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(lane 2) showed a band with a molecular mass of approximately 65 kDa. The 
glycosylated form of NAMLAA, purified li'OIll human plasma, had a molecular 
mass of 70 kDa (lane I). The cytosol fraction and the specific granule containing 
fraction were stained very faintly. 
DISCUSSION 
The two most impOltant enzymes capable of degrading peptidoglycan in 
humans are lysozyme and NAMLAA. Lysozyme is present in specific and 
azurophilic granules of neutrophils [23,24) and in the granules of monocytes [25), 
but its presence was not detectable in eosinophilic granulocytes [26,27). NAMLAA 
is expressed differently. It is present in the azurophilic granules of neutrophils and 
in the crystalloid containing granules of eosinophilic granulocytes. In a previous 
study, in which we investigated the inflammatory propelties of peptidoglycan 
products before and after NAMLAA degradation, we found that the cooperative 
action of lysozyme and NAMLAA is essential for optimal degradation of 
peptidoglycan. The difference in localization between NAMLAA and lysozyme is 
therefore remarkable. 
Azurophilic granules store a number of digestive enzymes, which are 
essential for the inactivation of invading microorganisms. Using some of these 
enzymes as a marker, Egesten et a!. [28) were able to classify heterogeneous 
forms of azurophilic granules in promyelocytes. By using antibodies against 
myeloperoxidase (MPO), bactericidal permeability increasing protein, cathepsin G, 
elastase and proteinase 3, they classified azurophilic granules into nucleated 
azurophils, large spherical azurophils and small azurophils. In Fig. 6b it is shown 
that NAMLAA did not always colocalize with MPO, which suggests that 
NAMLAA is also heterogeneously expressed between the different forms of 
azurophilic granules. 
In previous studies it was shown that NAMLAA is a glycoprotein with a 
molecular mass of 70 kDa, and 60 kDa after deglycosylation [3). Using two-
dimensional gel electrophoresis, we detected mUltiple isoforms ofNAMLAA with 
the main spots between pH 7.5 and 7.8. This proves that NAMLAA is a cationic 
protein, as are most of the proteins in the azurophilic granules [28). The neutrophil 
fractions subjected to Western blot analysis showed a broad protein band with a 
molecular mass between the fully glycosylated 70 kDa band and the deglycosyla-
ted 60 kDa band. The molecular mass and the broadness of the band indicate that 
the enzyme may have been pattly degraded during the isolation procedure. The 
presence of the band in the azurophil fraction but not in the fraction containing the 
specific granules confirms the results obtained by immunoelectron microscopy. 
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The fact that the membrane fraction also contained the same band indicates that 
NAMLAA possibly associates with membranes, perhaps as a result of fusion of 
secretory vesicles or azurophil granules with the plasma membrane. 
The NAMLAA-positive cells in the tissues tested were granulocytes 
migrated into the tissues and granulocytes present in the blood vessels of the 
tissues. Surprisingly, the NAMLAA-containing cells in the liver were not Kupffer 
cells, which are known to be involved in the clearing of bacterial debris from the 
circulation. Why these cells do not express NAMLAA is unknown, but it is 
consistent with the findings of Daldorff et al. [29] and Lichtmann et al. [30] who 
showed in a rat model that bacterial cell walls can persist for long times in the 
liver. 
The expression ofNAMLAA during the maturation of the myeloid lineage 
shows that NAMLAA expression starts early in granulocyte maturation and late 
in monocyte/macrophage maturation. This difference is probably related to the 
effector function of these cell types. Monocytes are actually precursor cells of 
macrophages and may not need NAMLAA for their effector function in this stage, 
while granulocytes and macrophages are mature phagocytizing cells. The 
expression pattern of NAMLAA during myeloid differentiation shows that 
NAMLAA is also expressed in the megakatyocyte lineage, corresponding with the 
finding that thrombocytes in blood were also stained positive for NAMLAA. 
In conclusion, the results presented in this paper demonstrate the presence 
of a novel enzyme, capable of degrading bacterial cell walls, in azurophylic 
granules of neutrophilic, in the cristalloid containing granules of eosinophilic 
granulocytes, thrombocytes and a sub-population of activated alveolar macropha-
ges. The expression pattern of NAMLAA in the myeloid lineage suggest that 
AAA4 is useful for discrimination between AML in the monocyte lineage and in 
the granulocyte lineage. Therefore AAA4 might contribute to the diagnosis and 
classification of acute leukemias. The cloning of the gene coding for NAMLAA 
is in progress. 
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ABSTRACT 
N-acetylmuramyl-L-alanine amidase (NAMLAA) is a relatively unknown 
human serum enzyme which cleaves the amide bond between N-acetylmuramic 
acid and L-alanine of the peptide side chain of bacterial peptidoglycan. Lysozyme 
degrades peptidoglycan differently by hydrolyzing the amino-sugar backbone of 
peptidoglycan and has been shown to act synergistically with NAMLAA. The 
presence of lysozyme and NAMLAA, which are both produced by granulocytes, 
was determined in serum and cerebrospinal fluid (CSF) of patients with bacterial 
meningitis. As could be expected based on the literature and cell counts, lysozyme 
was found in CSF while surprisingly, NAMLAA was not present. In previous 
studies it was shown that NAMLAA was able to reduce the inflammatory 
properties of peptidoglycan. The absence of NAMLAA in CSF could have 
important consequences for the pathogenesis of Gram-positive bacterial meningitis. 
INTRODUCTION 
N-acetylmuramyl-L-alanine amidase (NAMLAA) hydrolyses peptidoglycan 
by cleaving the lactamide bond between N-acetyl muramic acid and the peptide 
side chain. NAMLAA together with lysozyme, which hydrolyses the aminosugar 
backbone of peptidoglycan, can degrade peptidoglycan to less or non-inflammatory 
subunits as found in a recent study [1]. Although the presence and action of 
lysozyme in body fluids is described in an overwhelming number of papers, only 
4 investigations on NAMLAA in human serum have been reported [2-5). 
We previously described a colorimetric method for the determination of 
NAMLAA in serum and other body fluids [5), the purification ofNAMLAA from 
human plasma, its localization in granulocytes and the biological significance of 
the enzyme [1,6]. Until now we were able to determine NAMLAA in every 
human serum tested (n> 100). 
It is well known that during bacterial meningitis granulocytes enter the 
cerebrospinal fluid (CSF). Determination of lysozyme in CSF was reported to be 
indicative for Gram-positive meningitis [7,8). We assumed that, since both 
NAMLAA and lysozyme are present in granulocytes, amidase would be excreted 
and detected in CSF samples from patients with bacterial meningitis which contain 
lysozyme. To test this assumption we investigated Selllm and CSF of patients with 
bacterial meningitis due to Streptococcus pneumolliae, Neisseria menillgitidis and 
Haemophilus itif!uenzae. As controls we used CSF samples of patients with non-
septic neurologic diseases. 
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METHODS 
Patients and controls 
Patients between the age of 3 months and 18 rears who were diagnosed with bacterial 
meningitis between August 1992 and September 1994 were suitable for inclusion. The patients were 
admitted by the Departments of Pediatrics of the Sophia Children's Hospital and Zuiderziekenhuis, 
both in Rotterdam, Reinier de Graaf Gasthuis in Delft and Juliana Children's Hospital in The I-Iague. 
Bacterial meningitis was defined as the presence of a positive bacterial culture from CSF or the 
presence of a positive blood culture in combination with clinical evidence of meningitis and a CSF 
white blood cell (WBC) count above tOx1061L. Patients with prior antibiotic treatment were 
excluded. Control samples of CSF were obtained from 10 patients from the Department of 
Neurology. Lumbar punctures in these patients were performed for diagnostic reasons, hut infection 
was not present. CSF samples from patients and controls were examined for WBC cOllnt and levels 
of glucose and protein. Sera from to healthy subjects (20M45 years) were used as controls. 
Collection of samples 
Samples of blood and CSF in children with bacterial meningitis were obtained on admission 
prior to the initiation of antibiotic treatment and during treatment of the first 24 h at 6, 12 or 24 h. 
Blood was collected into sterile siliconized vacutainer glass tubes (Becton Dickinson, Meylan Cedex, 
France) and allowed to clot at room temperature. CSF samples were collected into pyrogenMfree 
polystyrene tubes (Fa1conR, Becton Dickinson, Franklin Lakes, NJ). The samples were centrifuged 
at 2800 g at 4°C for to minutes. The supernatants were stored at M70°C until used. 
Laboratory studies 
Cultures of blood and CSF were processed according to standard procedures [9]. The CSF 
WBC count, glucose and protein concentration were determined by routine laboratory procedures in 
each of the participating hospitals. 
Lysozyme 
The lysozyme concentration in sera and CSF was detemlined with a turbidimetric assay 
according to the method of Klass and Neale [to] with some modifications. In short, a suspension of 
5 mg Micrococclis Iysodeikliclis (Sigma, st. Louis, MO) per ml NH4Ac (0.5 M) pH 6.5 was used 
as substrate for lysozyme activity. 12.5 ~I Serum and CSF samples were diluted with 187.5 ~I bidest 
and subsequently 50 J.l1 substrate was added. Samples were incubated in 96 well microtiter plates at 
37'C during I h on a Titertek shaker (Flow Lab, Scotland). The standard curve of chicken egg white 
lysozyme (Sigma) was linear up to 20 J.lg/ml. Samples above this limit were brought into the range 
by dilution. Absorption was determined in a Titertek Multiscan (Flow Lab, Irvine, Scotland) at 620 
nm. The detennination was carried out in duplicate for each sample. Data are expressed as J.lg 
lysozyme per ml, Determinations in 5 fold showed standard deviations of less than 10%. 
NAMLAA 
NAMLAA activity in sera and CSF was determined as described by Hazenberg and de Visser 
[5] and Holjer et al [6] with some modifications. In short: Peptidoglycan monomers from 
BrevibacterillmdivaricalulJI (ATCC 14020) were used as a substrate. 50 J.lI 100 fold diluted serum 
or CSF in 0.02 M NH4HC03 buffer (pH 8.0) and 50 "I substrate diluted in buffer to a final 
concentration of 400 J.lg NMacetylmuramic acid (the characteristic aminosugar of peptidoglycan) were 
incubated for 15 min at 37°C, The increase in the concentration of NMacetyimuramic acid 
110 
NAAfLAA and lysozyme in CSF 
corresponds with peptide side chains released from the aminosugar due to NAMLAA activity. This 
was measured with a colorimetric method using a Titertek Multiscan. Ow I 00 J.lg Nwacetylmuramic 
acid solutions served as a standard. The determination was carried out in duplicate for each sample 
and data are expressed as Vlml scmm or CSF. One unit of enzyme activity was defined as the 
liberation of I /.-lmol Nwacetylmuramic acid from peptide side chains per minute. Determinations in 
5wfold resulted in standard deviations of less than 5%. 
Immunofluorescence labeling and flowwcytometric analysis 
Labeling of AAA4, a human NAMLAA specific monoclonal antibody developed in our 
laboratory [6], with fluorescein isothiocyanate (FITe) was performed according to standard 
procedures [II]. Human peripheral blood cells were stained for intracellular antigens according to 
Syrjaltl et al [12]. In short, 100 ~I citrate blood was incubated with CDI5-PE (Immuno Quality 
Products, Groningen, The Netherlands) in PBS + 0.5% BSA for to min. The cells were then lysed 
and fixed by adding 2 ml of FACS lysing solution (Becton Dickinson) and incubating for 10 min 
at room temperature. The cells were centrifuged and washed twice with PBS + 0.5% BSA. Then the 
mouse AAA4wFITC was added and the mixture was incubated for 10 min at room temperature. The 
cells were washed twice with 2 ml PBSwBSA and finally resllspended in 200 /.-ll FACS flow (Becton 
Dickinson). The analyses were perfonned using a FACScan cytofluorometer (Becton Dickinson, 
Sunnyvale, CAl. 
Table 1. Clinical and laboratory characteristics of 18 children with bacterial meningitis and 
10 contl'ol subjects with nonwinfectious neurologic diseases 
Age (years) 
Sex (No.) 
male 
female 
Microworganisms (No.) 
H. injluenzae 
N. meningitidis 
S. pneumoniae 
Others 
Cerebrospinal fluid 
WBC count (/mm3) 
glucose (mmollL) 
protein (gIL) 
Meningitis patients 
(n~18) 
3.8 
(0.3 - 13.0) 
6 . 
12 
8 
5 
5 
6438 
(96 - 34000) 
1.6 
«0.1 - 4.2) 
1.9 
(0.5 - 8.0) 
Except as indicated, data are expressed as median (range). WBe • white blood cells. 
III 
Control patients 
(FlO) 
57.5 
(24 - 83) 
5 
5 
3 
(0 - 50) 
3.8 
(1.8 - 4.7) 
0.46 
(0.11 - 5.4) 
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RESULTS 
Patients and controls 
The clinical and laboratory characteristics of patients and control subjects 
are shown in Table 1. Eighteen patients with a proven bacterial meningitis were 
enrolled. The CSF samples showed lower glucose and high protein concentrations 
indicative of bacterial meningitis. CSF samples from the neurologic non-infectious 
control patients were sterile. The median age (range) of the control groups 
(neurologic patients as well as healthy subjects) was significantly higher than that 
of the meningitis patients. 
Table 2. NAMLAA activity and lysozyme levels in sera and cerebrospinal fluid of patients with 
S. pJlelllllolliae, H. illjlueJJlOe and No mellillgilidis meningitis and in control groups 
NAMLAA') 
patients serum CSF 
S. pnelllJloniae 2.1 (1.4-2.S) 0.0 (0.0·1.1) 
(n~5) (n~13) (n~6) 
N. menillgitidis 2.7 (2.3·3.3) 0.0 (0.0·0.3) 
(n~5) (n~ll) (n~S) 
H. influel1zae 2.2 (1.6·3.2) 0.0 (0.0·0.2) 
(n~S) (n~20) (n~13) 
Neurologic non~ 0.1 (0.0·0.3) 
infectious (n~lO) (n~lO) 
Healthy subjects 2.S (1.6·4.0) 
(n~lO) (n~lO) 
.) Concentration in Vlml. median and range, and number of samples 
H) Concentration in ~lg!ml, median and range, and number of samples. 
NAMLAA and lysozyme in serum and CSF 
.. ) lysozyme 
serum CSF 
7.5 (6.4·9.1) 
(n~l3) 
7.0 (4.S·S.4) 
(n~ll) 
7.3 (4.3-S.S) 
(n~20) 
6.7 (4.4·S.2) 
(n~lO) 
4.9 (1.3-7.0) 
(n~6) 
7.0 (3.5-S.6) 
(n~S) 
7.1 (5.1-10.0) 
(n~l3) 
0.0 (0.0-5.2) 
(n~lO) 
NAMLAA and lysozyme were determined in serum and CSF. The results 
are presented in Table 2. Lysozyme was found in similar concentrations in serum 
of bacterial meningitis patients and healthy controls. Significant differences in 
concentrations on admission (n=6) after 6 h (n=II), after 12 h (n=13) and after 
24 h (n=14) were not observed. Lysozyme levels in CSF of meningitis patients 
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were high and not different from those found in the sera. Differences in 
concentrations in the observed time period 0 to 24 h were not seen. In the non-
meningitis control group lysozyme was not found in CSF. 
NAMLAA activity was not or barely detectable in CSF of the meningitis 
patients. Addition of purified NAMLAA [6] to samples showed that activity was 
not inhibited by CSF (data not shown). In several samples the enzyme activity was 
determined more than once and the results were always consistent. 
DISCUSSION 
Normal values of lysozyme and NAMLAA activity were found in the sera 
of patients with a bacterial meningitis. The presence of lysozyme in the CSF of 
the meningitis patients was expected on the basis of leukocyte counts in the 
samples and the confirmation of meningitis. Porstmann et al. [7] and Ribero et al. 
[8] using an ELISA and Iysoplate method, respectively, (the latter is comparable 
with our method) both found lysozyme concentrations in CSF samples from 
patients with bacterial meningitis as high as senlln levels. In both studies the 
control CSF from multiple sclerosis patients (n=9), patients with "disturbances in 
CSF circulation" (n= II) and control subjects without bacterial meningitis (n=54) 
contained concentrations of lysozyme less than 5% of serum or CSF values in 
patients with bacterial meningitis. 
Although no information on the presence ofNAMLAA in CSF is available, 
the complete absence in lysozyme positive CSF specimens was surprising. Two 
possible explanations for the phenomenon are: (I) passage of the smaller lysozyme 
(14 kDa) via an impaired blood brain barrier to the CSF (molecular mass of 
NAMLAA is 70 kDa [6]) or (2) active excretion of lysozyme by granulocytes in 
the CSF compartment but not of NAMLAA or other proteolytic enzymes. 
In a rabbit model of meningitis it has been shown that PG can provoke 
inflammation resulting in brain edema, leukocytosis and protein accumulation in 
the CSF. Solubilized PG was lO-foid more active in this model than intact cell 
walls [13,14]. Previous studies showed that after lysozyme treatment bacterial cell 
wall fragments still possessed inflammatory properties, such as the induction of 
IL-I, IL-6 and TNF -0: release by macrophages and arthritis induction in a rat 
model, while after NAMLAA treatment the inflammatory properties were 
significantly reduced [I]. This indicates that the synergistic activity ofNAMLAA 
and lysozyme is essential for the degradation and inactivation of peptidoglycan 
products. It is therefore possible that during Gram-positive bacterial meningitis cell 
wall fragments are not sufficiently degraded in CSF because of the absence of 
113 
Chapter 7 
NAMLAA. This very intriguing hypothesis needs further investigation to reveal 
whether NAMLAA in combination with antibiotics could prevent the symptoms 
seen during Gram-positive bacterial meningitis. 
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General discussion 
GENERAL DISCUSSION 
Rheumatoid arthritis [I] and inflammatory bowel diseases like Crohn's 
disease [2,3] and Ulcerative Colitis [2,3] are described in the literature as 
inflammatory diseases with unknown etiology. By a number of authors it has 
been suggested that peptidoglycan-polysaccharides (PG-PS) originating from 
bacterial cell walls, might be the triggering antigen [4-6]. This hypothesis is 
supported by several reports which show that PG-PS are able to induce 
inflammation. An overview on the inflammatory properties of PG-PS is given 
in chapter I of this thesis. 
A prerequisite for the hypothesis that PG-PS is involved in inflammatory 
diseases is that these bacterial cell wall products can occur in relevant human 
tissues. However, hardly any evidence for the presence of PG-PS in human 
tissues can be found in the literature. This is probably due to technical difficul-
ties in detection and purification of PG-PS. By employing sophisticated 
methods, Lethonen et al. [7] recently showed the presence of muramic acid 
(Mur), the characteristic aminosugar of PO (See introduction, Fig. I), in 
synovial fluid of patients with an acute inflammatory arthritis of unclear origin 
but who had a histOlY of bacterial disease. In chapter 2 of this thesis a mono-
clonal antibody recognizing PO-PS was used for the detection of these antigens 
in synovial tissues of m1hritis patients and healthy controls. PO-PS was found 
to be present in tissue macrophages and dendritic cells that PO can cause 
inflammation. Both our results as well as the results of Lethonen et al. [7,8] 
suggest an involvement of inflammatory PO-PS products in the pathogenesis of 
human chronic polyarthritis. This suggestion is further strengthened by the 
results obtained from experiments using animal models. 
In animal models PO-PS was shown to be present in synovial tissue 
macrophages [9] suggesting that these cells playa major role in transport of 
PG-PS to the synovial tissues. The capacity of PO to induce arthritis has been 
extensively investigated in animal models for arthritis [10]. In these models it 
was shown that PG-PS persisted in tissue macrophages for more than 90 days 
after the injection of PG-PS [II]. Lichtman et al. [12] investigated the role of 
macrophages in this respect. They supp0l1ed the hypothesis that PO can cause 
inflammation by showing that PO-PS containing liver macrophages of rats were 
able to induce inflammation. The results strongly suggest that the presence and 
persistence of PO-PS in tissues is likely to be imp0l1ant in the pathogenesis of 
idiopathic arthritis. 
In our immunohistochemical studies and the studies of Lethonen et al. 
[7,8] it was not necessary to purifY the PO-PS from tissues. The purification of 
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these PG products, however, can give information on the molecular shucture in 
which PG is present in tissues. The purified products could also be used in 
studies to test their inflammatory capacity, which would be very important in 
the elucidation of the role of PG in the pathogenesis of inflammatory diseases 
with unknown etiology. For this reason the purification of PG from human 
spleen was performed, as described in chapter 3. A macromolecular carbo-
hydrate-rich fraction was obtained after several purification steps. We confir-
med the presence of PG in this fraction by the detection of Mur using an 
aminosugar/aminoacid analysis method. Further investigations on the nature of 
the purified PG products will most likely elucidate whether these products 
possess inflammatory properties. 
The presence of PG in the human bowel wall [13], synovia [14], and 
spleen [15], suggests that human tissues are continuously exposed to PG. It is 
clear that these inflammatory bacterial cell wall products, which can be translo-
cated across the bowel wall [16] or released during an bacterial infection, need 
to be removed from the circulation. 
Bacterial cell walls are rapidly cleared by the action of phagocytic cells 
and their hydrolytic enzymes. Since Fleming discovered lysozyme in human 
tissues in 1922 [17], this enzyme was thought to be responsible for lysing 
invading bacteria and subsequent degradation of PG. Later it was found that 
lysozyme only pattly degrades PG from several bacteria [18,19]. The degra-
dation of PG by lysozyme was shown to be dependent on the degree of 0-
acetylation of MurNAc in the aminosugar backbone of PG [20] (see Fig. 2, 
chapter 1). The studies described in chapter 5 of this thesis show that after 
lysozyme treatment cell wall fragments still possess inflammatory propelties in 
an animal model for arthritis. 
Therefore, the presence of another potent PG degrading enzyme N-
acetylmuramyl-L-alanine amidase (NAMLAA) in human serum, described for 
the first time by Ladesic et al. [21], drew ouI' attention. The possibility that this 
enzyme could degrade PG in such a way that it would loose its inflammatory 
properties, pushed our interest in the direction of this enzyme. 
In chapter 4 the purification and characterization of NAMLAA from 
human plasma is described. The generation of monoclonal antibodies against 
NAMLAA made it possible to prepare an immuno-affinity column with which 
it was relatively simple to purify NAMLAA from plasma. The concentration of 
NAMLAA in serum was estimated to be around 10 Itg/ml. NAMLAA was 
characterized as a glycoprotein of 70 kDa with an iso-ele~tric point between 7.5 
and 7.9 and a specific enzymatic activity of 46 Itg PG monomer.min-l.mg- l . 
The purified enzyme was further used to investigate its biological function. We 
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felt that degradation of PG by NAMLAA could result in the inactivation of the 
inflammatory properties of PG. To test this idea, the in vivo adjuvant arthritis 
model was used as a measure for the inflammatory capacity of a bacterial cell 
wall preparation from EubacteriuIII aerojaciens (ECWF). As is described in 
detail in chapter 5, degradation of ECWF by lysozyme results in a preparation 
which was still al1hritogenic. However, after lysozyme and subsequent NAM-
LAA degradation the ECWF had completely lost the arthritis inducing capacity. 
Inflammation processes have a relation with the induction of IL-l, IL-6, 
IL-S and TNF-u [22]. These pro-inflammatory cytokines are reported to play 
an imp0l1ant role in the pathogenesis of septic shock [23], pertussis [24,25], 
arthritis [26] and possibly in all bacterially induced inflammatory diseases. PG 
was described to be able of inducing cytokine release by human monocytes 
[27]. Therefore this propel1y was also used to investigate the influence of 
lysozyme and NAMLAA degradation. 
Mice were intravenously injected with ECWF digested with either 
lysozyme, NAMLAA or both to test the cytokines released in the blood. In 
vitro, the same ECWF digests were tested by stimulating whole blood 01' 
isolated human peripheral blood monocytes. We found in both test systems that 
the cytokine inducing capacity of NAMLAA degraded ECWF was much lower 
than after treatment with lysozyme alone. 
These results are the first to show that NAMLAA is capable of decrea-
sing the inflammatory properties of bacterial cell wall fi·agments. Because 
NAMLAA acts specifically on the PG part of the ECWF, the results also show 
now in a completely different way that the inflammatory properties of ECWF 
are for an important part related to the PG component. 
Due to the rapid increase in bacterial species and strains which are 
multiresistant for antibiotics, it is plausible that treatment of the symptoms, 
induced by bacterial infections, will become more and more imp0l1ant. Excessi-
ve release of the inflammatory cytokines IL-l, IL-6, IL-S and TNF -u have 
become synonymous with various clinical pathologies due to bacterial infecti-
ons. Knowledge about the mechanisms responsible for the release of inflamma-
tory cytokines is therefore important for future treatment of infections. To 
prevent the symptoms caused by these cytokines one can either block the 
production of cytokines 01' the activity of the produced cytokines. The latter 
possibility has been investigated using TNF-u inactivating monoclonal antibo-
dies. The administration of these monoclonal antibodies has been shown to be 
beneficial for rheumatoid arthritis patients as well as for patients with Crohn' s 
disease [25,27]. Whether NAMLAA administration may be used to reduce the 
production of pro-inflammatory cytokines is a challenging question which will 
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be investigated in the future, especially for bacterial meningitis (see chapter 7). 
The localization of NAMLAA in tissues might give further evidence for 
its biological role in humans. We used the monoclonal antibody AAA4 for 
immunohistochemistry, immuno electron microscopy, FACScan and Western 
blot studies to investigate the localization of NAMLAA. The results described 
in chapter 6 of this thesis show the localization of NAMLAA in several human 
tissues which finally led to the discovery that NAMLAA is present in granulo-
cytes. More detailed studies using immuno electron microscopy revealed the 
presence of NAMLAA in the azurophilic granules of neutrophilic granulocytes 
and in the crystalloid containing granules of eosinophilic granulocytes. The 
azurophilic granules also contain other bactericidal enzymes [29]. An interes-
ting obsel'Vation is that MPO-positive azurophilic granules were not all positive 
for NAMLAA, suggesting that the azurophilic granules do not form a homoge-
nous population. This was also reported by Egesten et a!. [30], who defined 3 
different granule populations in neutrophilic granulocytes, based on differences 
in protein contents. 
The localization of NAMLAA in granulocytes is not very surprising 
because the phagocytic cells are involved in the first line defence against 
invading bacteria or bacterial products. The absence of NAMLAA in monocy-
tes, however, did come as a surprise because these cells are capable of phago-
cytizing bacteria and are well equipped for the killing of bacteria. 
The absence of NAMLAA in monocytes possibly explains the observed 
presence of PG-PS in macrophages [9] as well as the finding that cultured 
monocytes release biologically active PG products into the medium after 
phagocytosis of Staphylococcus al/rel/S cells [31]. The combined results suggest 
that due to the absence of NAMLAA, the cell wall fragments can persist and 
remain biologically active in monocytes and macrophages. It can be hypothesi-
zed that the PG products in these cells are structurally different from the 
products which can be degraded by lysozyme and NAMLAA and are subse-
quently excreted in the urine [32]. 
The expression of NAMLAA during the maturation of granulocytes is 
described in chapter 6. To investigate the maturation stage in which NAMLAA 
is expressed for the first time, cells from various acute myeloid leukemic 
(AML) patients were used. Fig. 5 of chapter 6 shows the myeloid differentiati-
on lineages together with the FAB classification. NAMLAA is expressed in the 
myelocyte lineage from AML-M2 to mature granulocytes and in AML-M7 
classified cells which are immature megakaryoblast cells. From the mature 
cells, platelets and granulocytes expressed NAMLAA. If NAMLAA can be 
used as a differentiation marker for AML patients needs further investigation 
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with higher numbers of patients. The preliminary results show that the AML-
M2 classified cells can be subdivided into two groups based on NAMLAA 
expression. More M2 samples should be investigated to confirm this subdivi-
sion. 
As is described in chapter 7, NAMLAA is absent in cerebrospinal fluid 
(CSF) of bacterial meningitis patients. In a rabbit model of bacterial meningitis 
it has been shown that PG can provoke inflammation resulting in brain edema, 
leukocytosis and protein accumulation in the CSF. Solubilized PG was 10 fold 
more active in this model than intact cell walls [33]. If during a Gram-positive 
bacterial infection, PG is released into the CSF due to the action of antibiotics 
on the bacterial cell walls, the PG fragments cannot be fllliher degraded 
because NAMLAA is absent in this compmiment. This vety intriguing observa-
tion needs fllliher investigation to reveal whether NAMLAA in combination 
with antibiotics may prevent the symptoms seen during Gram-positive bacterial 
meningitis. 
Apart fi'om the already mentioned suggestions for future research, more 
basic questions in NAMLAA research are mentionable as well. For example 
cloning of the gene encoding for human NAMLAA would provide great 
possibilities for fllliher research. The generation of knock-out mice, assuming 
homology in the human and mouse gene, is one of the possibilities. In these 
animals the biological function of NAMLAA in the non-specific immune 
system could be established in vivo. The ability of granulocytes lacking 
NAMLAA, to digest phagocytized bacteria 01' bacterial products, would be 
interesting as well. The cloning of the gene would also allow the in vitro 
production of NAMLAA which would make the purification of NAMLAA 
independent of human plasma. 
The tools required for the detection of the NAMLAA gene have been 
prepared. DNA expression libraries from human granulocytes and normal 
human bone marrow have been prepared recently, and the screening of these 
libraries can be performed, using the monoclonal antibodies we prepared 
previously against human NAMLAA. 
Another approach to find the NAMLAA gene is by PCR techniques. 
The N-tenninal aminoacid sequence of NAMLAA is known and recently three 
other peptides obtained after CNBr digestion were sequenced. It is possible to 
prepare degenerated primers based on the amino acid sequences, which can be 
used in PCR experiments [34). 
The results described and discussed in this thesis add a new and impor-
tant human enzyme to the list of anti-bacterial enzymes known until now. The 
results will hopefully lead to more research on the role of NAMLAA in non-
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specific inflammation, caused by (peptidoglycan containing) bacterial cell wall 
fi"agments. 
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SUMMARY 
The cell wall surrounding the bacterial cytoplasmic membrane, which 
gives the cell its strength, contains several components which can be involved 
in the pathogenesis of bacterial infectious diseases. One of these components is 
the macromolecular peptidoglycan (PG). Previous to the research described in 
this thesis, it was found that cell wall fragments of some bacteria from the 
normal human gut flora were arthritogenic in Lewis rats. This led to the 
hypothesis that PG plays a major role in the pathogenesis of inflammatory 
diseases with unknown etiology like rheumatoid arthritis (RA). 
In order to be able to induce inflammation, PG must of necessity be 
present in tissues. However, the presence of PG in human tissues has not been 
shown before. Using immunohistochemical techniques, we found (chapter 2) 
that PG is present in macrophages and dendritic cells of the synovia (from knee 
joints) of patients with RA (80%) and to a lesser extent in the synovia of 
control patients (35%). The presence of PG in antigen presenting cells supports 
the hypothesis that PG is involved in the induction of inflammation in the 
affected synovia. 
The purification of PG fragments from human tissues would make it 
possible to investigate the inflammatory properties of these PG products and to 
characterize their composition. Chapter 3 describes the purification of a macro-
molecular, PG-containing, polysaccharide fraction from human spleen which 
was biochemically analyzed. These studies showed for the first time that 
macromolecular PG products are present in human tissues. 
The presence of PG in inflamed tissues is a prerequisite assuming that 
PG can trigger inflammation. On the other hand, the degradation of PG is 
probably needed to prevent excessive inflammatory reactions. Two human 
enzymes are capable of significant degradation of PG: lysozyme and N-acetyl-
muramyl-L-alanine amidase (NAMLAA). In order to elucidate the possible 
anti-inflammatOlY role of the latter, NAMLAA was purified from human 
plasma (chapter 4). The development of monoclonal antibodies directed against 
NAMLAA improved the purification procedure. The characteristics of the 
purified enzyme were then determined. 
To investigate the effect of NAMLAA on PG, we used two properties of 
PG: the capability of PG to induce 31thritis in Lewis rats and the capability to 
induce the inflammatory cytokines interleukin-I, interleukin-6 and tumor 
necrosis factor-a in vivo and in vitro (chapter 5). The results showed that after 
degradation of cell wall fi·agments by lysozyme and NAMLAA the 31thritis-
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inducing capacity was completely lost, whereas after degradation by NAMLAA 
or lysozyme alone the cell wall fragments were still aI1hritogenic. Upon 
injection of PG in mice and after incubation of human blood monocytes with 
PG, the induction of cytokine release was lower after the combined PG 
degradation by lysozyme and NAMLAA compared to the degradation of PG by 
lysozyme or NAMLAA alone. The results show that NAMLAA, together with 
lysozyme, inactivates inflammatory PG. 
In chapter 6, the monoclonal antibodies directed against NAMLAA were 
used to detect which cells produce NAMLAA. Using immunohistochemistry 
and flow cytometty, it was found that NAMLAA was expressed by neutrophilic 
and eosinophilic granulocytes. Thrombocytes were also positively stained for 
NAMLAA, but monocytes were negative. The localization of NAMLAA and 
lysozyme showed remarkable differences. Eosinophilic granulocytes expressed 
NAMLAA but not lysozyme, and monocytes expressed lysozyme but not 
NAMLAA. This is surprising because the experiments described in chapter 5 
showed that lysozyme and NAMLAA work synergistically. 
Chapter 7 describes another striking difference in the localization of 
NAMLAA and lysozyme. Cerebrospinal fluid normally does not contain 
lysozyme or NAMLAA activity. Patients suffering from a bacterial meningitis 
are known to possess elevated levels of lysozyme activity in the cerebrospinal 
fluid, sometimes even higher than in serum. We confirmed these findings, but 
NAMLAA activity was not detected in the same samples! The absence of 
NAMLAA might have important consequences for the pathogenesis of the 
disease. It is likely that the absence of NAMLAA gives rise to an increase in 
insufficiently degraded cell wall fragments, which might cause excessive 
cytokine production. Whether the administration of NAMLAA into the cere-
brospinal fluid can suppress the symptoms should be investigated. 
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SAMENVATTING 
De celwand die om de cytoplasmamembraan van de bacterie zit en de cel 
zijn stevigheid geeft, bevat een aantal componenten die een belangrijke rol 
kunnen spelen in de pathogenese van sommige infectieziekten. Peptidoglycaan 
(PG), een zeer groot molecuul dat als een gevlochten netwerk om de bacterie 
heen zit, is een dergelijke celwandcomponent. Vit voorgaand proefdieron-
derzoek is gebleken dat PG van sommige bacterien van de normale humane 
dannflora gewrichtsontstekingen kan induceren bij Lewis ratten na eenmalige 
intraperitoneale of subcutane injectie. Dit onderzoek heeft geleid tot de hypo-
these dat PG een belangrijke rol speelt in de pathogenese van ontstekingen met 
een onbekende oorzaak zoals reumatolde mtritis (RA). 
De aanwezigheid van PG in de relevante weefsels is een voorwaarde 
voor de juistheid van de hypothese. PG was echter nog n iet eerder aangetoond 
in humane weefsels. Met immunohistochemische technieken werd gevonden 
(Hoofdstuk 2) dat PG aanwezig is in macrofagen en dendritische cellen van 
synovia (van knie gewrichten) van patienten met RA (80 %) en in mindere 
mate (35%) in synovia van "gezonde" controle patienten. De aanwezigheid van 
PG in deze voor de immuunreactie zo belangrijke antigeen presenterende cellen 
ondersteunt de hypothese dat PG betrokken kan zijn bij de inductie van ontste-
kingen in de synovia. 
Nadat ook in de humane milt immunohistochemisch PG was aangetoond, 
werd daaruit een PG-bevattende fractie gelsoleerd, die het mogelijk maakt om 
deze PG produkten te karakteriseren en de invloed ervan op het immuunsys-
teem te onderzoeken. Hoofdstuk 3 beschrijft de zuivering van een macl'Omole-
culaire PG f1'actie uit humane milt, waarbij de fractie op biochemische wijze 
werd geanalyseerd. Met de resultaten beschreven in de hoofdstukken 2 en 3 is 
de aanwezigheid van macl'Omoleculaire PG produkten in humane weefsels voor 
het eerst komen vast te staan. 
Als de aanwezigheid van PG in weefsels ontsteking kan induceren, dan is 
de afbraak van PG pl'Odukten van belang tel' voorkoming van dergelijke ontste-
kingsreacties. Twee humane enzymen die PG kunnen afbreken zijn hiervoor 
van belang: het zeer bekende Iysozym en het vrijwel onbekende N-acetylmura-
myl-L-alanine amidase (NAMLAA). Om de betekenis van NAMLAA voor de 
PG-afbraak te onderzoeken, werd dit enz)'m gezuiverd uit bloedplasma (Hoofd-
stuk 4). Met door ons ontwikkelde monoklonale antistoffen kon het enz)'m 
efficient met immunoaffiniteitschromatografie worden ge'isoleerd en konden de 
specifieke kenmerken van dit enz)'m worden bepaald. 
In hoofdstuk 5 werd onderzocht wat de gevolgen zijn van PG-afbraak 
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door NAMLAA op het vermogen tot atiritisindllctie in Lewis ratten en inductie 
van de afgifte van de ontstekingsmediatoren interleukine-I, interlellkine-6 en 
tllmornecrosefactor-u ill vivo en ill vitro. Daartoe werd PG ge'incllbeerd met 
aileen NAMLAA en met zowel NAMLAA als Iysozym. Na afbraak van 
celwandfragmenten door Iysozym en NAMLAA was het vermogen om artritis 
te indllceren in Lewis ratten volledig verloren gegaan, terwij I na afbraak door 
aileen Iysozym of aileen NAMLAA het PG preparaat nog steeds aIiritogeen 
was. Ook de inductie van cyiokine afgifte was in aile gebruikte testsystemen 
lager na afbraak door Iysozym en NAMLAA samen. De resllltaten tonen aan 
dat NAMLAA en Iysozym synergistisch werken en samen in staat zijn om PG 
die ontstekingen en ontstekingsmediatoren induceren, af te breken. 
De monoklonale anti stoff en die door ons werden ontwikkeld, zijn 
gebruikt om te bepalen waar, in welke cellen en weefsels, NAMLAA aanwezig 
is (Hoofdstuk 6). Met behlllp van immunohistochemie en flowcyiometrie werd 
gevonden dat NAMLAA in neutrofiele en eosinofiele granulocyten tot expressie 
komt. Bloedplaatjes bleken eveneens positief aan te kleuren met de monoklona-
Ie antistoffen tegen NAMLAA. Monocyten waren echter niet positief voor 
NAMLAA. Opvallend is dat het verschillende celtypen zijn die aankleuren voor 
Iysozym en NAMLAA: eosinofiele granulocyten brengen weI NAMLAA tot 
expressie maar geen Iysozym, en voor monocyten geldt het omgekeerde. Deze 
cellen brengen weI Iysozym, maar geen NAMLAA tot expressie. Dit is verras-
send omdat in hoofdstuk 5 werd aangetoond dat Iysozym en NAMLAA 
synergistisch werken. 
Hoofdstuk 7 beschrijft nog een opmerkelijk verschil in voorkomen van 
NAMLAA en Iysozym. Cerebrospinale vloeistof bevat nOl'lnaal geen Iysozym 
en ook geen NAMLAA activiteit. Het was al langeI' bekend dat bij patienten 
met een bacteriele meningitis het gehalte aan Iysozym in de cerebrospinale 
vloeistof sterk verhoogd kan zijn, soms zelfs hoger dan in het serum van de 
patient. Dit vonden wij ook, maar in dezelfde monsters was geen NAMLAA 
activiteit aantoonbaar! De afwezigheid van NAMLAA kan belangrijke gevolgen 
hebben: het is waarschijnlijk dat door de afwezigheid van NAMLAA de PG 
fragmenten in de cerbrospinale vloeistof onvoldoende worden afgebroken, 
waardoor zij inflammatoire cytokinen kunnen indllceren. Of toediening van 
NAMLAA aan de cerebrospinaale vloeistof ontstekingsremmend werkt, zal 
onderzocht moeten worden. 
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ABBREVIATIONS 
Ala 
AML 
APAAP 
BSA 
CSF 
CWF 
Dpm 
ECWF 
ELISA 
FITC 
FPLC 
FAB 
GlllcNAc 
GMDP 
HPLC 
i.p. 
!soGln 
IsoGlu 
kDa 
LF 
LPS 
LTA 
Lys 
MDP 
MoAb 
MPO 
MTT 
Mill' 
MIII'NAc 
NAM 
NAMLAA 
Orn 
PBMC 
PG-PS 
pI 
RA 
alanine 
acute myeloid leukemia 
alkaline phosphatase mouse-ant i-alkaline phosphatase complex 
bovine senUll albumin 
cerebrospinal fluid 
cell wall fragments 
diamino pimelic acid 
Eubacterium aerofaciens cell wall fragments 
enzyme-linked immunosorbent assay 
fluorescein isothiocyanate 
fast performance liquid chromatography 
French-American-British 
N-acetylglucosamine 
N-acetylglucosamine-N-acetylmuramic acid dipeptide 
high performance liquid chromatography 
intraperitoneal 
Iso-glutamine 
Iso-glutamate 
kilo dalton 
lactoferrin 
lipopolysaccharide 
lipotcichoic acid 
lysine 
mummyl dipeptide 
monoclonal antibody 
myeloperoxidase 
3 -[4 ,5-d imethylthiazol-2-yl]-2,5-diphenyltetrazo I hUll bromide 
muramic acid 
N-acetyl muramic acid 
N-acetyl muramic acid 
N-acetylmuramyl-L-alanine amidase 
ornithine 
peripheral blood mononuclear cells 
peptidoglycan polysaccharides 
isoelectric point 
rheumatoid arthritis 
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SDS-PAGE 
Ser 
TCT 
Thr 
WBC 
sodium dodecylsulphate-polyacrylamide gel electrophoresis 
serine 
tracheal cytotoxin 
threonine 
white blood cells 
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